US Pat. No. 10,112,867

CHEMICALLY STRENGTHENED GLASS AND METHODS OF MAKING SAME

International Business Ma...

1. A method for use in preparing a glass, the method comprising:performing a first ion exchange process to replace at least a first ion in the glass with at least a second ion, the second ion being smaller than the first ion; and
performing a second ion exchange process to replace at least the second ion in the glass with at least a third ion, the third ion being larger than the first ion.
US Pat. No. 10,111,842

EUTECTIC SOLVENTS AND USES THEREOF

University of Oslo, Oslo...

1. A method of killing or inhibiting the growth of a bacterial cell, fungal cell, or cancer cell, comprising:contacting said cell with a composition comprising a eutectic solvent and a photosensitizer selected from the group consisting of a porphyrin compround, a chlorin compound, a bacteriochlorin compound , a phthalocyanine compound, a texaphyrin comppund, a sapphyrin compound a porphycene compound, a curcuminoid compound, and a flavin compound.
US Pat. No. 10,112,868

METHOD FOR POST-CONSUMER WASTE SEGREGATION, COMMINUTION, AND CREATION OF CEMENTITIOUS AGGREGATE MATERIAL

1. A method for post-consumer waste segregation, comminution, and creation of a cementitious aggregate material comprising the steps of:shredding partially processed post-consumer waste to a reduced size said partially processed post-consumer waste comprising:
non-metallic waste;
plastic waste;
to ferrous waste;
zorba;
entering said shredded waste into a processing stream;
magnetically forcing ferrous waste from the processing stream;
comminuting partially processed post-consumer waste to a reduced, standardized particulate size of consistent bulk density;
adding silica to the processing stream and binding of the silica to plastic waste particles by action of heat effective to form an insulating cementitious aggregate, whereby bulk density of plastic waste particles is increased relative other, non-plastic waste in the processing stream and any static cling between plastic particles and other non-plastic waste particles is obviated;
subjecting the processing stream to eddy currents devised to forcibly eject zorba away from remaining non-metallic waste;
collecting non-metallic waste separated from recyclable metallic waste;
directing zorba for reclamation of recyclable metals; and
collecting the cementitious aggregate free of metallic waste;
wherein separation of plastic waste from ferrous waste and zorba is rendered effective to enable reclamation of ferrous and non-ferrous metals from the waste stream during creation of a cementitious aggregate segregable for use as a building material.
US Pat. No. 10,111,843

METHODS FOR TREATING BRAIN INJURY

Hough Ear Institute, Okl...

1. A method for increasing the bioavailability of a compound in the central nervous system, the method comprising the steps of:administering 2,4-disulfonyl a-phenyl tertiary butyl nitrone to an organism in an amount sufficient to increase blood-brain barrier permeability; and
administering the compound to the organism either concurrently or following administration of 2,4-disulfonyl a-phenyl tertiary butyl nitrone.
US Pat. No. 10,111,844

LYOPHILIZED MESNA COMPOSITIONS

AUXIN SURGERY SA, Louvai...

1. A method of performing surgery comprising administering a lyophilizate composition having improved stability and shelf-life at a cleavage plane of a patient on which the surgery is performed, the lyophilizate composition consisting of 30 to 100% of Mesna and 0 to 70% of additional ingredients selected from the group consisting of excipient, buffering agent, Mesna disulfide and other impurities, wherein a sum of the percentage of the Mesna disulfide and the other impurities is lower than 3%.
US Pat. No. 10,112,356

METHOD OF PRODUCING A FILAMENT WOUND CURVED PRODUCT AND PRODUCT OBTAINED THEREBY

DSM IP ASSETS B.V., Heer...

1. A filament winding process for producing a 3D curved product comprising: (a) winding a plurality of reinforcing elements having a tensile strength of at least 1.6 GPa onto a mandrel which substantially approximates an inner shape of the 3D curved product to form a 3D curved fiber structure preform having a shape which substantially approximates the 3D curved product, (b) impregnating the plurality of reinforcing elements or the 3D curved fiber structure preform with a polymer matrix comprised of a solution and/or a dispersion of a polymer in a carrier fluid, (c) at least partly evaporating the carrier fluid from the solution and/or dispersion during and/or after winding the reinforcing elements onto the mandrel according to step (a), (d) consolidating the 3D curved fiber structure preform under elevated pressure onto the mandrel to thereby form the 3D curved fiber structure preform having a shape which substantially approximates the 3D curved product, (e) cutting the 3D curved fiber structure preform thereby also removing the mandrel, and (f) subjecting the fiber structure to a subsequent pressing process at elevated temperature and pressure to form the 3D curved product, wherein the reinforcing elements are present in an amount of at least 85% of the total mass of the 3D curved product.
US Pat. No. 10,112,870

SELF-DESICCATING, DIMENSIONALLY-STABLE HYDRAULIC CEMENT COMPOSITIONS WITH ENHANCED WORKABILITY

UNITED STATES GYPSUM COMP...

1. A cementitious composition comprising a reaction product of a mixture of:a hydraulic cement-based reactive powder comprising:
an aluminate cement selected from at least one member of the group consisting of calcium aluminate cement and calcium sulfoaluminate cement in an amount of 30-75 parts by weight per 100 parts by weight of the hydraulic cement-based reactive powder,
Portland cement in an amount of 5-35 parts by weight per 100 parts by weight of the hydraulic cement-based reactive powder, and
a calcium sulfate selected from the group consisting of calcium sulfate dihydrate, calcium sulfate hemihydrate, anhydrous calcium sulfate and mixtures thereof, the calcium sulfate in an amount of 20-40 parts by weight per 100 parts by weight of the hydraulic cement-based reactive powder;
an inorganic flow control agent in a weight ratio of inorganic flow control agent to hydraulic cement-based reactive powder of 0.5:1 to 2.0:1, wherein the inorganic flow control comprises at least one member selected from the group consisting of fly ash and calcium carbonate and wherein average particle size of the calcium carbonate ranges from about 10 to 150 microns;
a metal-based dimensional movement stabilizing agent in an amount equal to 1.0 to 4.0 weight percent of the hydraulic cement-based reactive powder, wherein the metal-based dimensional movement stabilizing agent comprises a lithium compound selected from at least one member of the group of lithium salt and lithium base, wherein the lithium salt is at least one member of the group of lithium carbonate, lithium sulfate, lithium nitrate, lithium nitrite, and lithium silicate, wherein the base is lithium hydroxide;
a filler in a weight ratio of filler to hydraulic cement-based reactive powder of 0.5:1 to 3.5:1; and
water in a weight ratio of water to hydraulic cement-based reactive powder of 0.6:1 to 1.3:1.
US Pat. No. 10,111,845

VALPROIC ACID FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION

Cereno Scientific AB, Go...

1. A method of treating or reducing the risk of a pathological condition associated with excess fibrin deposition and/or thrombus formation in a subject in need thereof, comprising administering to the subject at least one dose of a therapeutically effective amount of valproic acid, or a pharmaceutically acceptable salt thereof, wherein the maximum plasma concentration (Cmax) of the valproic acid, or salt and/or metabolite thereof in the subject after administration occurs during a time period that is from four hours before to one hour after the Cmax of PAI-1 in the subject.
US Pat. No. 10,112,871

CARBONATE-BONDED CONSTRUCTION PRODUCTS FROM STEEL-MAKING RESIDUES AND METHOD FOR MAKING THE SAME

1. A method for making a construction block, comprisingproviding granular material and a binder consisting of steel slag;
combining the granular material, the binder with water to a first water-to-slag ratio;
molding the combined granular material, binder and water;
reducing the quantity of water in the molded granular material, binder and water to a second water-to-slag ratio that is lower than the first water-to-slag ratio;
curing said molded granular material, binder and water having said second water-to-slag ratio with carbon dioxide.
US Pat. No. 10,111,846

S ISOMERS OF ALPHA-METHYL-HYDROCINNAMIC ACID FOR THE TREATMENT OF BLOOD DISORDERS

1. A method for treating a subject, comprising administering to the subject an oral pharmaceutical formulation comprising:a. a pharmaceutically effective amount of an S isomer of ?-methyl-hydrocinnamic acid, or a pharmaceutically acceptable salt thereof; and
b. a pharmaceutically acceptable carrier or diluent,
wherein the oral pharmaceutical formulation comprises less than 6% of the R isomer of ?-methyl-hydrocinnamic acid and wherein the oral pharmaceutical composition is in solution or a dry solid,
wherein the oral pharmaceutical formulation is administered to the subject by oral administration, and
wherein the subject has been selected for administration of the oral pharmaceutical composition as one who will undergo a chemotherapeutic treatment or a radiation treatment or radiation exposure after the administration of the oral pharmaceutical formulation.
US Pat. No. 10,113,128

FLUORINE-CONTAINING AGENTS FOR ENHANCING HYDRATE INHIBITORS

Ecolab USA Inc., St. Pau...

1. A method for inhibiting gas hydrate agglomeration in a fluid comprising a hydrocarbon and water, the method comprising adding to the fluid an effective amount of a gas hydrate-inhibiting composition, the composition comprising an anti-agglomerant agent and a fluorine-containing agent comprising a fluoroalkyl moiety, the hydrate-inhibiting composition inhibiting gas hydrate agglomeration in the fluid.
US Pat. No. 10,115,948

SEPARATOR FOR A NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS SECONDARY BATTERY

TEIJIN LIMITED, Osaka (J...

1. A separator for a non-aqueous secondary battery, comprising:a porous substrate, and
an adhesive porous layer that is coated on one side or both sides of the porous substrate, contains (1) the following polyvinylidene fluoride resin A and (2) the following polyvinylidene fluoride resin B, and has a porosity of from 30% to 52% and an average pore size of from 36 nm to 100 nm:
(1) polyvinylidene fluoride resin A selected from the group consisting of vinylidene fluoride homopolymers, and vinylidene fluoride copolymers containing structural units derived from vinylidene fluoride and structural units derived from hexafluoropropylene, a total content of structural unit derived from hexafluoropropylene in each of the vinylidene fluoride copolymers being 1.5 mol % or less of a total content of structural unit in each of the vinylidene fluoride copolymers; and
(2) polyvinylidene fluoride resin B selected from the group consisting of vinylidene fluoride copolymers containing a structural unit derived from vinylidene fluoride and a structural unit derived from hexafluoropropylene, a total content of structural unit derived from hexafluoropropylene in each of the vinylidene fluoride copolymers being greater than 1.5 mol % of a total content of structural unit in each of the vinylidene fluoride copolymers,
wherein, in the adhesive porous layer, a content of the polyvinylidene fluoride resin A is from 15 parts by mass to 40 parts by mass, and a content of the polyvinylidene fluoride resin B from 60 parts by mass to 85 parts by mass, when a total amount of the polyvinylidene fluoride resin A and the polyvinylidene fluoride resin B is taken as 100 parts by mass.
US Pat. No. 10,111,847

COMPOUNDS AND METHODS FOR MODULATING VASCULAR INJURY

The Regents of the Univer...

1. A method of reducing inflammatory response of vascular smooth muscle cells of a vascular wall to vascular injury or restenosis of a vascular wall following injury, the method comprising:positioning a vascular device at or adjacent the vascular wall,
wherein the vascular device releases a pro-resolving lipid mediator in an amount sufficient to reduce the inflammatory response to the vascular injury or restenosis of the vascular wall,
wherein the vascular device is a stent or a perivascular wrap,
wherein the pro-resolving lipid mediator comprises Maresin-1, RvD1, or RvD2.
US Pat. No. 10,112,873

CERAMICS WITH ENGINEERED MICROSTRUCTURES VIA 3D PRINTING AND TEMPLATED GRAIN GROWTH

RAYTHEON COMPANY, Waltha...

1. A three-dimensional (3D) printing composition, comprising:ceramic filaments, each ceramic filament comprising an additive and having an extrusion direction, at least 50% of the additive of each ceramic filament being aligned with respect to the extrusion direction, and each additive having an aspect ratio of at least 2:1.
US Pat. No. 10,111,848

TRIHEPTANOIN FOR THE TREATMENT OF GLUCOSE TRANSPORT 1 DEFICIENCY

National Institute of Hea...

1. A method of treating a movement disorder associated with GLUT1 deficiency in a human subject in need thereof, the method comprising administering to the human subject an effective amount of triheptanoin, wherein the movement disorder is selected from dystonic movements, ataxia, chorea, tremors, dysarthria, and myoclonus.
US Pat. No. 10,114,924

METHODS FOR PROCESSING OR ANALYZING SAMPLE OF THYROID TISSUE

Veracyte, Inc., South Sa...

1. A method for processing or analyzing a sample of thyroid tissue of a subject, comprising:(a) obtaining said sample of thyroid tissue of said subject, wherein said subject has or is suspected of having thyroid cancer, and wherein said sample of thyroid tissue comprises gene expression products;
(b) subjecting a first portion of said sample of thyroid tissue to cytological testing that indicates that said first portion of said sample of thyroid tissue is indeterminate;
(c) upon identifying said first portion of said sample of thyroid tissue as indeterminate, assaying by sequencing, array hybridization, or nucleic acid amplification, said gene expression products from a second portion of said sample of thyroid tissue, to yield a data set including data corresponding to gene expression product levels;
(d) in a programmed computer, inputting said data including said gene expression product levels from (c) to a trained algorithm to generate a classification of said sample of thyroid tissue as positive or negative for said thyroid cancer at an accuracy of at least 90%, wherein said trained algorithm is trained with a plurality of training samples, and wherein said sample of thyroid tissue is independent of said plurality of training samples; and
(e) electronically outputting a report that identifies said classification of said sample of thyroid tissue as positive or negative for said thyroid cancer.
US Pat. No. 10,115,950

METHOD OF PREPARING SEPARATOR FOR LITHIUM SECONDARY BATTERY, SEPARATOR PREPARED THEREFROM, AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME

LG Chem, Ltd., (KR)

1. A method of preparing a separator for a lithium secondary battery, comprising:(S1) bringing polymer particles into electric charging to obtain electrically charged polymer particles;
(S2) transferring the electrically charged polymer particles on at least one surface of an inversely electrically charged porous polymer substrate to form an electrode-adhesion layer whose area ranges from 1 to 30% based on a total area of the porous polymer substrate; and
(S3) fixing the electrode-adhesion layer with heat and pressure,
wherein a solvent is not used to form the electrode-adhesion layer.
US Pat. No. 10,111,849

USE OF MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM II

Accera, Inc., Denver, CO...

1. A method of treating loss of cognitive function caused by Alzheimer's disease or Mild Cognitive Impairment in a patient that is ApoE4(?), the method comprising:orally administering a dosage unit of medium chain triglyceride to said patient in need thereof such that the blood level of D-beta-hydroxybutyrate in the patient is raised to about 0.1 to 50 mM causing hyperketonemia in the patient, wherein the patient has a diet wherein carbohydrate intake is not restricted, resulting in ketone bodies being utilized for energy in the brain to thereby treat loss of cognitive function,
wherein the dosage unit is given in a single dose.
US Pat. No. 10,111,850

ESTER AND CHOLINESTERASE INHIBITOR IN LONG-ACTING NERVE BLOCK

1. A pharmaceutical composition comprising about 10 mg to about 100 mg tetracaine or pharmaceutically acceptable salt thereof and about 100 ?g to about 1000 ?g physostigmine or pharmaceutically acceptable salt thereof.
US Pat. No. 10,113,132

COUPLED PHENOLS FOR USE IN BIODIESEL ENGINES

The Lubrizol Corporation,...

1. A lubricating oil composition containing or contaminated with at least about 0.1 wt. % of a biodiesel fuel or a decomposition product thereof, based on the total weight of the lubricating oil composition, said lubricating composition further comprising an oil of lubricating viscosity and about 0.5 to about 5 weight percent of an antioxidant selected from the group consisting of 2,2?-Methylenebis[4-methyl-6-t-butylphenol], 2,2?-Methylenebis[4-ethyl-6-t-butylphenol], 2,2-Methylenebis[4-methyl-6-[?-methylcyclohexyl)phenol], and any combination thereof.
US Pat. No. 10,111,852

METHOD FOR TREATING BLADDER CANCER

The William M. Yarbrough ...

1. A method for treating bladder cancer, comprising the step(s) of:administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
US Pat. No. 10,112,878

MOLECULAR SIEVES MEDIATED UNSATURATED HYDROCARBON SEPARATION AND RELATED COMPOSITIONS, MATERIALS, METHODS AND SYSTEMS

CALIFORNIA INSTITUTE OF T...

1. A method to separate an eight-membered monocyclic unsaturated hydrocarbon at an initial concentration Ci, from a hydrocarbon mixture further comprising additional nonlinear unsaturated C8H2m hydrocarbons with 4?m?8, the method comprisingproviding a 10-ring pore molecular sieve having a sieving channel with a 10-ring sieving aperture with a minimum crystallographic free diameter greater than 3 ? and a ratio of the maximum crystallographic free diameter to the minimum crystallographic free diameter between 1 and 2,
the 10-ring pore molecular sieve having a T1/T2 ratio?20:1 wherein T1 is an element independently selected from Si and Ge or a combination thereof, and T2 is an element independently selected from Al, B and Ga or a combination thereof,
the 10-ring pore molecular sieve further having a counterion selected from NH4+, Li+, Na+, K+ and Ca++ or a combination thereof, and
contacting the hydrocarbon mixture with the 10-ring pore molecular sieve at a temperature of ?20° C. to 60° C. for a time and under conditions to obtain a sieved hydrocarbon mixture comprising the eight-membered monocyclic unsaturated hydrocarbon at a separation concentration Cs>Ci.
US Pat. No. 10,113,134

CAPPED OIL SOLUBLE POLYALKYLENE GLYCOLS WITH LOW VISCOSITY AND HIGH VISCOSITY INDEX

Dow Global Technologies L...

1. A capped oil soluble polyalkylene glycol having the following structure:R1O-(AO)n—R2
where: R1 is a linear or branched alkyl or aryl with one to 18 carbon atoms; AO refers to residuals of monomers selected from 1,2-butylene oxide and 1,2-propylene oxide selected so that at least 50 weight-percent of the (AO)n, component is 1,2-butylene oxide residuals; n is a number from 3 to 7 and is selected to provide a kinematic viscosity at 100 degrees Celsius of less than 5 centiStokes for the non-capped polyalkylene glycol; and R2 is a linear or branched alkyl or aryl having from 1-8 carbon atoms and wherein the capped oil soluble polyalkylene glycol is characterized by having a kinematic viscosity of less than 4.5 centiStokes at 100 degrees Celsius and a viscosity index of greater than 150.
US Pat. No. 10,112,365

METHOD FOR PROVIDING A CARRIER MATERIAL

1. A method for providing a two dimensional carrier material for vinyl floor covering, roofing underlayment sheet or bitumen roofing membrane comprising a nonwoven layer of fibers and threads extending in the longitudinal direction of the carrier material, comprising:supplying a nonwoven layer of fibers,
supplying a scrim comprising warp threads and weft threads adjacent and co-planar to the nonwoven layer of fibers, the warp threads extending in the longitudinal direction of the carrier material and comprising high modulus yarns having a modulus of at least 1 GPa, and
thermally bonding the scrim to the nonwoven layer of fibers
wherein the weft threads of the scrim are predominantly made of a polymer having a melting temperature which is equal to or less than the lowest melting temperature of the fibers comprised in the nonwoven layer of fibers and which is less than the melting temperature of at least a part of the warp threads of the scrim, the weft threads comprising the polymer in an amount of at least 95 percent by weight, and
wherein the weft threads of the scrim are fully melted during thermal bonding of the scrim to the nonwoven layer of fibers such that the weft threads are no longer present as a continuous phase after thermal bonding.
US Pat. No. 10,112,879

PROCESS TO MANUFACTURE 2-CHLORO-1,1,1,2-TETRAFLUOROPROPANE (HCFC-244BB)

HONEYWELL INTERNATIONAL I...

1. A process for the production of 2-chloro-1,1,1,2-tetrafluoropropane which comprises reacting 2-chloro-3,3,3,-trifluoropropene with hydrogen fluoride, in a liquid phase reaction in the presence of hydrogen chloride and a liquid phase fluorination catalyst, wherein the hydrogen chloride is added into the reaction from an external source at a pressure of about 100 psig or more.
US Pat. No. 10,113,135

PERFUMING METHOD

KAO CORPORATION, Tokyo (...

1. A perfuming method, comprising:applying a water-based product that comprises a perfume precursor to a fabric or a human body;
drying the water-based product; and
subsequently bringing the perfume precursor into contact with moisture in the air to perform hydrolysis, thereby releasing a perfume,
wherein the water-based product comprises a perfume precursor comprising an ester of i) at least one perfume selected from the group consisting of maltol, ethyl maltol, ethyl vanillin, and raspberry ketone, and ii) at least one aliphatic monocarboxylic acid or aliphatic dicarboxylic acid selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid, and sebacic acid.
US Pat. No. 10,111,854

SYNTHESIS AND USE OF AMINE-CONTAINING FLAVONOIDS AS POTENT ANTI-LEISHMANIAL AGENTS

The Hong Kong Polytechnic...

1. An anti-leishmanial compound having the general formula of:Flavonoid-X—NR1R2 or Flavonoid-X—R1R2,
or a pharmaceutically acceptable salt thereof,wherein:the flavonoid is selected from the group consisting of flavone, flavonol, flavanone, and isoflavonoid;
X is a linker, wherein each linker independently comprises one or more groups selected from the group consisting of alkylene, ethyleneoxy, propyleneoxy, butyleneoxy, alkylC(O)—, ethylene amine, propylene amine, butylene amine, alkylcyclic amine, alkylcyclic diamine, or a combination thereof;
wherein:
(i) R1 is independently selected from the group consisting of H, —(CH2)n-aryl, and —(CH2)n-heteroaryl which may be optionally substituted; R2 is independently selected from the group consisting of H, —(CH2)n-aryl, and —(CH2)n-heteroaryl which may be optionally substituted; or
(ii) R1R2 forms a cyclic compound with a general structure of —(CH2)n—Y—(CH2)m— wherein Y is CH2, O, or NR1, any of which may be optionally substituted; and
wherein n and m are independently selected from an integer between 1 to 6.
US Pat. No. 10,111,855

USE OF EQUOL FOR TREATING ANDROGEN MEDIATED DISEASES

Brigham Young University,...

1. A method of modulating androgen hormone action to ameliorate or enhance at least one condition of the skin or hair of a subject, comprising administering a composition composing racemic equol, wherein the racemic equol binds free 5?-dihydrotestosterone and inhibits its binding with the androgen receptor, and wherein ameliorating or enhancing at least one condition of the skin or hair of the subject comprises at least one of:a) enhancing antioxidant content of the skin;
b) reducing skin inflammation;
c) improving skin thickness;
d) reducing skin adipose tissue (fat) and cellulite formation;
e) enhancing skin blood flow;
f) enhancing collagen and elastin;
g) improving skin abrasions and the appearance of scars;
h) enhancing wound healing;
i) diminishing skin pigmentation or dermal age spots;
j) enhancing skin lightening;
k) diminishing facial hair (hirsutism) or body hair; and
l) reducing skin oil production.
US Pat. No. 10,113,137

FABRIC SOFTENER ACTIVE COMPOSITION

Evonik Degussa GmbH, Ess...

1. A fabric softener active composition, comprising:a) as component A, at least 50% by weight of a bis-(2-hydroxypropyl)-dimethylammonium methylsulphate fatty acid ester having a molar ratio of fatty acid moieties to amine moieties of from 1.5 to 1.99, an average chain length of the fatty acid moieties of from 16 to 18 carbon atoms and an iodine value of the fatty acid moieties, calculated for the free fatty acid, of from 0.5 to 50; and
b) as component B, a (2-hydroxypropyl)-(1-methyl-2-hydroxyethyl)-dimethylammonium methylsulphate fatty acid ester having the same fatty acid moieties as component A;wherein the molar ratio of component B to component A is from 0.05 to 0.20.
US Pat. No. 10,111,856

COMPOSITION FOR PREVENTING OR TREATING CLIMACTERIC SYMPTOMS COMPRISING SOYBEAN EXTRACT COMPRISING COUMESTROL AS AN ACTIVE INGREDIENT

AMOREPACIFIC CORPORATION,...

1. A method for preventing or treating a climacteric disease, wherein the method comprises administering an effective amount of a germinated and fermented bean extract comprising coumestrol to a subject in need thereof, wherein the method is for preventing or treating a climacteric disease,wherein the fermented bean extract is a fermented product by Aspergillus oryzae of the germinated bean,
wherein the climacteric disease is osteoporosis.
US Pat. No. 10,113,138

APE-FREE SURFACTANT COMPOSITIONS AND USE THEREOF IN TEXTILE APPLICATIONS

Dow Global Technologies L...

1. A process of removing wax or oil from a textile material, comprising contacting the textile material with a composition comprising:an alkyl alkoxylate sulfate of formula I:
R1O—(CH2CH(R2)—O)x—(CH2CH2O)y—SO3M  (I);
a nonionic alkyl alkoxylate of formula II:
R1O—(CH2CH(R2)—O)x—(CH2CH2O) y—H  (II); and
waterwherein R1 is linear or branched C4-C10 alkyl;R2 is CH3 or CH3CH2;
x is a real number from 1 to 11;
y is a real number from 1 to 20; and
M is an alkali metal or NH4, andwherein R1, R2, x, and y in formula I and formula II may be the same or different.
US Pat. No. 10,111,857

MICROCAPSULES CONTAINING AN OXIDIZABLE ACTIVE, AND A PROCESS FOR PREPARING THE SAME

IDCAPS, La Rochelle (FR)...

1. A microcapsule consisting of:a single core consisting of an oxidizable active (OA), and at least one additional element selected from drying agents, antioxidant agents, filmogen agents and emulsifying agents, the outer part of said core being in a solid form; and
a water insoluble coating obtained from a water soluble encapsulating agent (EA) selected from alginates of monovalent cations, water insolubility being induced by a salt having a divalent metallic cation, said coating surrounding said core,
wherein said OA is selected from the group consisting of vitamin B5, vitamin B6, vitamin B8, vitamin B9, vitamin A, vitamin D3, vitamin K and vitamin E,
with the proviso that:
said core does not comprise a metal oxide, and
said coating does not comprise a disintegrant.
US Pat. No. 10,112,369

TRANSPARENT MULTILAYER FILM CONTAINING POLY(METH)ACRYLIMIDE-BASED RESIN LAYER, AND METHOD FOR PRODUCING SAID TRANSPARENT MULTILAYER FILM

RIKEN TECHNOS CORPORATION...

1. A transparent multilayer film, comprising:a first poly(meth)acrylimide resin layer (?1);
an aromatic polycarbonate resin layer ((?); and
a second poly(meth)acrylimide resin layer (?2), the layers being laminated directly in this order,
wherein the transparent multilayer film satisfies the following requirements (i), (ii) and (iii):
(i) a total light transmittance of higher than 90%;
(ii) (ii) a haze of 2.0% or lower; and
(iii) a retardation of 50 nm or lower.
US Pat. No. 10,112,883

PRODUCTION OF PRODUCTS FROM NATURAL RESOURCES

Saudi Basic Industries Co...

1. A method of producing acrylic acid and acetic acid comprising the steps of:a) providing a feedstream comprising syngas;
b) a step consisting of contacting the feedstream with a first catalyst to produce a first product stream comprising C2-C3 olefins and/or C2-C3 paraffins; and
c) contacting the first product stream with oxygen gas and a second catalyst, thereby producing a second product stream comprising acrylic acid and acetic acid,
wherein there is no step for separating the components of the first product stream before the first product stream is contacted with the second catalyst,
wherein the first catalyst is a catalyst composition comprising cobalt; manganese; hydrophilic silica; and at least one element comprising lanthanum, phosphorus, Fe, Zr, or Zn, wherein the relative molar ratios of the elements comprised in said composition are represented by the formula
Coa1Mnb1Siz1Xy1M1d1Of1,
wherein a1 is 1;
wherein b1 is from 0.8 to 1.2;
wherein Si is in the form of a hydrophilic silica;
wherein z1 is from 0.1 to 1;
wherein X is La, P, Fe, Zr, or Zn, or a mixture thereof;
wherein y1 is greater than 0 to 0.005;
wherein M1 is one or more elements selected from the group consisting of alkali metal, alkaline earth metal and transition metal,
wherein d1 is 0 to 0.005; and
wherein f1 is a number determined by the valence requirements of elements of the other elements present in the catalyst.
US Pat. No. 10,113,139

SOLID FABRIC CONDITIONER COMPOSITION AND METHOD OF USE

Ecolab USA Inc., Saint P...

1. A solid fabric softening composition comprising:(a) from about 5 wt. % to about 10 wt. % of one or more surfactants;
(b) from about 5 wt. % to about 20 wt. % of a polyethylene glycol with a molecular weight of 4000 (PEG-4000) or 8000 (PEG-8000) and about 19 wt. % to about 30 wt. % of urea as solidification agents; and
(c) from about 30 wt. % to about 45 wt. % of a quaternary ammonium component and about 5 wt. % to about 10 wt. % of an amino-functional silicone compound,
wherein the surfactants are a C10-C16 alcohol ethoxylate or mixtures thereof;
wherein the ester quaternary ammonium component is methyl bis[ethyl (tallowate)]-2-hydroxyethyl ammonium; and
wherein a ratio of the ester quaternary ammonium component to amino-functional silicone compound is between about 3:1 to about 9:1.
US Pat. No. 10,113,395

ORGANOPHILIC NANOPARTICLES IN DIRECT EMULSION SYSTEMS AND METHODS FOR THEIR USE AS WELLBORE DRILLING FLUIDS

M-I L.L.C., Houston, TX ...

14. A direct emulsion fluid comprising:an aqueous continuous phase;
an oleaginous discontinuous phase;
a phospholipid surfactant stabilizing the oleaginous discontinuous phase within the aqueous continuous phase; and
a viscosifier.
US Pat. No. 10,113,140

FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME

1. An air freshening composition, said composition comprising, based on total composition weight:a) a sum total of from about 0.0001% to about 15% of two or more malodor reduction materials selected from the group consisting of oxydibenzene, 2-isopropy 1-5-methylphenol, (Z)-non-6-en-1-ol, or combinations thereof; and
b) optionally, from about 0.01% to about 90 of at least one solvent;
c) optionally, an adjunct ingredient,
wherein the composition does not comprise water.
US Pat. No. 10,113,396

FRACTURING FLUIDS AND METHODS OF TREATING HYDROCARBON FORMATIONS

BAKER HUGHES, A GE COMPAN...

1. A method of fracturing a subterranean formation penetrated by a well, the method comprising:forming a fracturing composition comprising
a carrier fluid,
a proppant,
a superabsorbent polymer comprising a repeating unit derived from an acrylate, an acrylic acid or a salt thereof, an acrylamide, a vinylpyrrolidone, a vinyl ester, a vinyl alcohol, a 2-acrylamide-2-methylpropanesulfonic acid, a derivative thereof, or a combination thereof, the superabsorbent polymer having crosslinks derived from ethyleneglycol diacrylate, polyethyleneglycol diacrylate, trimethylopropane trimethacrylate, ethoxylated trimethylol triacrylate, ethoxylated pentaerythritol tetracrylate, or a combination comprising at least one of the foregoing,
a breaker effective to break the superabsorbent polymer at a temperature of greater than about 250° F. in the absence of any activators, the breaker comprising a bromate breaker,
an encapsulated activator comprising an activator encapsulated within an encapsulant, the activator comprising sorbic acid and being effective to activate the breaker so that the breaker or a derivative thereof breaks the superabsorbent at a temperature of less than about 200° F.;
pumping the hydraulic fracturing composition into the subterranean formation to create or enlarge a fracture;
allowing the activator to diffuse out of the encapsulant; and
breaking the superabsorbent polymer using the breaker,
wherein the fracturing composition is free of a crosslinking agent.
US Pat. No. 10,112,885

PROCESS AND SYSTEM FOR PRODUCING ACRYLIC ACID

Arkema Inc., King of Pru...

1. A process for the recovery of (meth)acrylic acid using coupled distillation columns comprising a dehydration column that is coupled to a finishing column such that a tails stream from the dehydration column is fed directly or indirectly into a top of the finishing column while an overhead stream of the finishing column is fed directly or indirectly into a base of the dehydration column, the process comprising:A. dehydrating a gaseous reaction mixture comprising (meth)acrylic acid in said dehydration column to produce a dehydration column overhead stream and a dehydration column bottoms stream, wherein the dehydrating step is carried out without using azeotropic solvent;
B. passing at least a portion of the dehydration column bottoms stream to the upper half of said finishing column;
C. subjecting the portion of the bottoms stream passed to the finishing column to distillation at less than atmospheric pressure within the finishing column to produce at least a finishing column overhead stream and a finishing column bottoms stream;
D. at least partially condensing the finishing column overhead stream using an overhead aspirating direct contact (ADC) condenser system to form a finishing column overhead condensate, and passing at least a portion of the finishing column overhead condensate to the dehydration column, wherein said ADC condenser system at least partially condenses the finishing column overhead stream and comprises at least one liquid jet eductor supplied with condensate from the finishing column overhead stream to generate a vacuum; at least one liquid-vapor separatory vessel; and at least one condensate cooler;
E. collecting (meth)acrylic acid from the finishing column; wherein said (meth)acrylic acid collected is technical grade containing at least 98.5% by weight (meth)acrylic acid, less than 0.5% water, and less than 0.4% acetic acid, and without producing a wastewater stream.
US Pat. No. 10,111,860

COMPOSITIONS AND METHODS FOR TREATING CONCUSSION

1. A method for treating concussion, the method comprising:administering a therapeutic dose of an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof.
US Pat. No. 10,112,888

NITROXIDE HYDROXYLAMINE AND PHENYLENEDIAMINE COMBINATIONS AS POLYMERIZATION INHIBITORS FOR ETHYLENICALLY UNSATURATED MONOMER PROCESSES

ECOLAB USA INC., St. Pau...

1. A method of inhibiting polymerization of isoprene comprising:providing a fluid comprising the isoprene;
adding an effective amount of a polymerization inhibitor composition to the fluid, wherein the polymerization inhibitor composition comprises an effective amount of 4-hydroxy-2,2,6,6-tetramethyl piperidinol and an effective amount of N,N?-di-1,4-dimethylpentyl-1,4-phenylenediamine; and
inhibiting polymerization of the isoprene.
US Pat. No. 10,112,119

METHOD FOR MODIFYING LOCAL PROPERTIES OF MATERIALS

Disney Enterprises, Inc.,...

1. A method for altering at least one local property of a primary material, comprising:reducing an elasticity of the primary material, wherein the primary material is an artificial skin material;
while the elasticity of the primary material is reduced, creating a delivery aperture through a portion of the primary material; and
introducing through the delivery aperture a secondary material into the primary material.
US Pat. No. 10,115,965

POSITIVE ACTIVE MATERIAL FOR RECHARGEABLE LITHIUM BATTERY, METHOD OF PREPARING SAME, AND RECHARGEABLE LITHIUM BATTERY INCLUDING SAME

Samsung SDI Co., Ltd., Y...

1. A positive active material for a rechargeable lithium battery, comprisinga core comprising a compound capable of intercalating and deintercalating lithium, the compound capable of intercalating and deintercalating lithium being a nickel-based oxide; and
a lithium metal phosphate on the surface of the core, the lithium metal phosphate being included in an amount of about 0.01 parts by weight to about 20 parts by weight based on 100 parts by weight of the compound capable of intercalating and deintercalating lithium,
wherein the lithium metal phosphate is different from the compound capable of intercalating and deintercalating lithium and is represented by Chemical Formula 1:
Li1+(x+y)InxMyTi2-(x+y)(PO4)3  Chemical Formula 1
wherein, in Chemical Formula 1, M is Al, Y, Sc, Mg, V, Cr, Mn, Fe, Ga, Lu, Cr, La, Ge, or a combination thereof, 0 wherein the nickel-based oxide comprises a lithium nickel cobalt aluminum oxide, a lithium nickel cobalt manganese oxide, or a combination thereof.
US Pat. No. 10,111,608

METHOD AND APPARATUS FOR PROVIDING DATA PROCESSING AND CONTROL IN MEDICAL COMMUNICATION SYSTEM

ABBOTT DIABETES CARE INC....

1. A method for notifying a user about an alarm condition without causing interruption to a predetermined routine, the method comprising:executing a concurrent passive notification routine on an analyte monitoring device, the concurrent passive notification routine comprising monitoring analyte levels received from a sensor for the alarm condition;
executing the predetermined routine comprising one or more of performing a finger stick blood glucose test, calibrating a sensor unit, configuring a device setting, reviewing historical glucose data, reviewing historical alarms, events, or entries in a data log, managing a data communication setting, transferring data to a data processing terminal, or reviewing a higher priority alarm condition;
in response to detecting the alarm condition by the concurrent passive notification routine during the execution of the predetermined routine, outputting to a user interface a first indication associated with the alarm condition, wherein the first indication is outputted during the execution of and without interruption to the predetermined routine; and
in response to a termination or a completion of the predetermined routine, outputting to the user interface by the concurrent passive notification routine a second indication for the alarm condition associated with the first indication.
US Pat. No. 10,113,146

METHOD OF COLLECTING PLACENTAL STEM CELLS

CELULARITY, INC., Warren...

1. A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood said method comprising:perfusing a placenta which has been drained of cord blood with an anticoagulant perfusion solution to flush out residual cells and embryonic-like stem cells from said drained placenta, and
collecting said residual cells and embryonic-like stem cells and perfusion solution from the drained placenta.
US Pat. No. 10,111,865

METHODS OF SEDATION DURING CRITICAL CARE TREATMENT

OVID THERAPEUTICS INC., ...

1. A method of sedating a patient undergoing critical care treatment comprising administering to the patient an effective amount of a pharmaceutical composition of gaboxadol or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,113,147

METHOD FOR PRODUCING MEGAKARYOCYTES, PLATELETS AND/OR THROMBOPOIETIN USING MESENCHYMAL CELLS

AdipoSeeds, Inc., Tokyo ...

1. A method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter so that the mesenchymal cell differentiates into a megakaryocyte and/or platelet, and collecting the megakaryocyte and/or platelet from a culture,wherein the mesenchymal cell is a CD31 negative and CD71 positive mesenchymal cell and wherein the medium does not contain exogenous thrombopoietin.
US Pat. No. 10,112,892

PROCESS FOR PREPARING POLYISOCYANATES

Covestro Deutschland AG, ...

1. A continuous process for liquid phase preparation of a polyisocyanate by reaction of a corresponding polyamine with phosgene, with a corresponding carbamoyl chloride and a corresponding amine hydrochloride occurring as intermediates, comprising:(i) mixing a phosgene-containing stream, a polyamine-containing stream and a stream containing carbamoyl chloride and amine hydrochloride in a mixing device to obtain a mixed stream, where phosgene is used in a stoichiometric excess of from >0% to 50% of theory, based on the amine groups of the polyamine present in the polyamine-containing stream;
(ii) conveying the mixed stream obtained in step (i) through a reactor in which an absolute pressure of from 20 bar to 60 bar and a temperature of from 80° C. to 200° C., prevail, thereby forming a stream containing carbamoyl chloride and amine hydrochloride;
(iii) optionally discharging a gaseous purge stream from the stream containing carbamoyl chloride and amine hydrochloride which is formed in step (ii), giving a stream which contains carbamoyl chloride and amine hydrochloride and has been depleted in gaseous components, and
(iv) dividing the stream containing carbamoyl chloride obtained in step (ii) or the stream contains carbamoyl chloride and amine hydrochloride and has been depleted in gaseous components obtained in step (iii) into two substreams, where
(a) one substream is used as the stream containing carbamoyl chloride and amine hydrochloride in step (i) and
(b) the other substream converted into the desired polyisocyanate.
US Pat. No. 10,113,148

METHOD FOR OBTAINING MONOCYTES OR NK CELLS

1. A method for obtaining monocytes or NK cells, comprising:(a) collecting a monocyte sample by separating the monocytes from peripheral blood by using an antibody specific for a surface marker of the monocytes, wherein the peripheral blood is obtained from a human;
(b) collecting, as an NK cell sample, cell populations remaining after the separation of the monocytes; and
(c) growing the monocytes or the NK cells by culturing at least one of the monocyte sample and the NK cell sample,
wherein in the step (c), at least the NK cells are grown by culturing the NK cell sample without carrying out further separation steps by use of a second medium containing an anti-CD56 antibody.
US Pat. No. 10,112,123

FRACTIONATOR FOR SEPARATING SOLUBILIZED RUBBER FROM A CO-SOLVENT BASED MISCELLA AND RELATED PROCESSES

Bridgestone Corporation, ...

1. A fractionator for separating solubilized rubber from a co-solvent based miscella, the fractionator comprising:a primary vessel comprising:
a feed inlet for feeding a co-solvent based miscella into the primary vessel, wherein the co-solvent based miscella separates to form (i) a non-polar solvent viscous rubber phase in a lower portion of the primary vessel and (ii) a polar solvent solubilized resin phase above the non-polar solvent viscous rubber phase;
a side outlet for removing the polar solvent solubilized resin phase from the primary vessel; and
a bottom outlet for removing the non-polar solvent viscous rubber phase from the primary vessel.
US Pat. No. 10,113,149

REPROGRAMMING OF HUMAN ENDOTHELIUM INTO HEMATOPOIETIC MULTI-LINEAGE PROGENITORS BY DEFINED FACTORS

CORNELL UNIVERSITY, Itha...

1. A method of generating human hematopoietic multi-lineage, progenitor cells (HMLPs) from human endothelial cells (ECs), comprising culturing human ECs expressing each of the transcription factors Finkel-Biskis-Dinkins murine osteosarcoma viral oncogene homolog B (FOSB), growth factor independent 1 transcription repressor (GFI1), Runt-related transcription factor 1 (RUNX1), spleen focus forming virus proviral integration oncogene (SPI1), in serum-free media with endothelial feeder cells, thereby generating HMLPs.
US Pat. No. 10,113,405

METHOD AND MATERIALS FOR HYDRAULIC FRACTURING WITH DELAYED CROSSLINKING OF GELLING AGENTS

Independence Oilfield Che...

1. A method of generating a fracture network within a subterranean formation penetrated by a wellbore, the subterranean formation having a permeability less than 10 mD, the method comprising:(A) pumping into the wellbore under shear an aqueous well treatment fluid comprising a crosslinking agent and a water-soluble gellant and delaying crosslinking between the crosslinking agent and the water-soluble gellant during pumping, wherein:
(a) the aqueous well treatment fluid when pumped into the wellbore has a viscosity less than 20 cP at 40 sec?1;
(b) the aqueous well treatment fluid comprises a non-aqueous slurry and the water-soluble gellant, wherein the non-aqueous slurry comprises (i) a non-aqueous liquid immiscible in water; (ii) an oil-wetting surface active material; and (iii) the crosslinking agent;
(c) the amount of the water-soluble gellant in the aqueous well treatment fluid is from about 6 to about 15 lb/1000 gal water; and
(d) the aqueous well treatment fluid increases in viscosity by forming a crosslinked gel from the water-soluble gellant and the crosslinking agent; and
(B) reducing the viscosity of the aqueous well treatment fluid by thermally thinning the aqueous well treatment fluid under in-situ conditions and generating a fracture network within the formation from the thermally thinned aqueous well treatment fluid.
US Pat. No. 10,111,868

ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE

WYETH LLC, New York, NY ...

1. A method for treating a neoplasm in a patient in need thereof, consisting of administering to the patient:i) 100-300 mg of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, or a pharmaceutically acceptable salt thereof; and
ii) vinorelbine, or a pharmaceutically acceptable salt thereof;wherein the neoplasm:a) overexpresses or amplifies HER-2; and
b) is selected from the group consisting of prostate cancer, myeloma, head and neck cancer, transitional cell carcinoma, and small cell and large cell neuroendocrine carcinoma of the uterine cervix.
US Pat. No. 10,113,150

ENGINEERED CARDIAC TISSUES AND METHODS OF USING THEM

InvivoSciences, Inc., Ma...

1. An engineered cardiac tissue comprising human cardiomyocyte cells comprising a transgene encoding a protein that results in resistance to a pharmacologic inhibitor wherein said transgene is operably linked to a cardiac-specific promoter, cardiac fibroblast cells and an extracellular matrix component, wherein the ratio of fibroblasts to cardiomyocytes is between 0.1:1 and 2:1, and wherein the tissue contracts coherently.
US Pat. No. 10,111,869

REDUCTION OF OPIOID BLOOD FLUCTUATIONS

ETHYPHARM, Saint-Cloud (...

1. A method of treatment of severe pain comprising administering orally to a patient in need thereof in a repeated manner twice-a-day a sustained-release matrix-type tablet releasing at least one opioid or one of its pharmaceutically acceptable salts, said matrix-type tablet comprising:a compression matrix consisting of granules of one opioid or one of its pharmaceutically acceptable salts and hydroxypropylmethylcellulose (HPMC); a mixture of microcrystalline cellulose and polyvinyl acetate/polyvinyl pyrrolidone (80:20); precipitated silica; and magnesium stearate;
a sub-coating consisting of a mixture of hydroxypropylmethylcellulose (HPMC), simethicone, micronized talc, and precipitated silica; and
a coating consisting of a mixture of an aqueous dispersion of ethylcellulose, dibutyl sebacate, talc, and precipitated silica;
wherein each administration being spaced apart by 8 to 14 hours, said method maintaining the steady-state opioid plasma concentration obtained in vivo with a reduced fluctuation at above 60% of the Cssmax value for at least 10 hours.
US Pat. No. 10,111,870

METHOD FOR INDUCING A SUSTAINED IMMUNE RESPONSE

1. A method for treating or preventing viral infections chosen from the group consisting of molluscum contagiosum infection, HTLV infection, HTLV-1 infection, hepatitis-A, HCV, HBV, HIV/AIDS infection, human papilloma virus infection, viral dysentery, flu, measles, rubella, chickenpox, mumps, polio, rabies, mononucleosis, ebola, respiratory syncytial virus, dengue fever, yellow fever, lassa fever, arena virus, bunyavirus, filovirus, flavivirus, hantavirus, rotavirus, viral meningitis, west Nile fever, arbovirus, parainfluenza, smallpox, Epstein-Barr virus, dengue hemorrhagic fever, cytomegalovirus, infant cytomegalic virus, progressive multifocal leukoencephalopathy, viral gastroenteritis, a hepatitis, meningitis, encephalitis, shingles, encephalitis, california serogroup viral, St. Louis encephalitis, rift valley fever, hand, foot, and mouth disease, hendra virus, enteroviruses, astrovirus, adenoviruses, Japanese encephalitis, lymphocytic choriomeningitis, roseola infantum, sandfly fever, SARS, warts, cat scratch disease, slap-cheek syndrome, orf, pityriasis rosea and lyssavirus in a mammal comprising administering to a patient in need thereof an immediate release pharmaceutical composition comprising between about 0.01 mg and about 10.0 mg of naltrexone or a pharmaceutically acceptable salt thereof wherein said immediate release pharmaceutical composition is to be administered alone or in combination with one or more antiviral agents.
US Pat. No. 10,111,871

NANOPARTICLE DRUG DELIVERY SYSTEM AND METHOD OF TREATING CANCER AND NEUROTRAUMA

Northeastern University, ...

1. A nanoparticulate formulation of an inhibitor of a poly (ADP-ribose) polymerase (PARP) enzyme, the formulation comprising a suspension of lipid vesicles in an aqueous medium, wherein the lipid vesicles have a positive surface charge, have an average diameter in the range from about 50 nm to about 200 nm, comprise a PARP inhibitor selected from olaparib and BMN-673, and comprise a PEGylated lipid moiety, wherein the effective concentration of the PARP inhibitor within the lipid vesicles is in the range from about 400 ?M to about 20 mM for olaparib or in the range from about 50 nM to about 1 ?M for BMN-673.
US Pat. No. 10,113,154

METHOD FOR PRODUCING STEVIOL GLYCOSIDE

SUNTORY HOLDINGS LIMITED,...

1. A polynucleotide selected from:a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1; and
a polynucleotide comprising a heterologous regulatory element operably linked to a polynucleotide sequence encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2.
US Pat. No. 10,113,155

STEVIOL GLYCOSYLTRANSFERASE AND GENE ENCODING SAME

SUNTORY HOLDINGS LIMITED,...

1. A polynucleotide selected from:a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1; and
a polynucleotide comprising a heterologous regulatory element operably linked to a polynucleotide sequence encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2.
US Pat. No. 10,113,156

STABILIZED REVERSE TRANSCRIPTASE FUSION PROTEINS

BOARD OF REGENTS, THE UNI...

1. A stabilized reverse transcriptase fusion protein comprising a thermostable group-II intron-derived reverse transcriptase connected at its N-terminus by a linker peptide to the C-terminus of a stabilizer protein including 50 or more amino acids, wherein the fusion protein exhibits increased solubility and stability in solution.
US Pat. No. 10,113,157

ALPHA-AMYLASE VARIANTS

1. A variant of a parent Termamyl-like alpha-amylase, comprising an alteration at one or more positions selected from the group of:W13, G48, T49, S50, Q51, A52, D53, V54, G57, G107, G108, A111, S168, M197, wherein (a) the alteration(s) are independently
(i) a deletion of the amino acid which occupies the position, or
(ii) a substitution of the amino acid which occupies the position with a different amino acid,
(b) the variant has alpha-amylase activity;
(c) each position corresponds to a position of the amino acid sequence of the parent Termamyl-like alpha-amylase having the amino acid sequence of SEQ ID NO: 4; and
(d) the variant has at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 41 or 42.
US Pat. No. 10,113,158

GLUCOAMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME

1. A glucoamylase variant having improved thermostability, comprising a substitution at a position corresponding to position 4 of the polypeptide of SEQ ID NO: 3, wherein the variant has glucoamylase activity and wherein the variant has at least 90% sequence identity to the polypeptide of SEQ ID NO: 3.
US Pat. No. 10,111,621

DISPOSABLE PRINTED CONDUCTIVE LEAD ELEMENTS FOR MEDICAL APPLICATIONS

Nikohed USA Inc., Hatbor...

1. A conductive lead for connecting a medical sensor to a machine, said conductive lead comprising:a dielectric flexible substrate extending a first length between a first end and a second end;
a first contact pad printed on said dielectric flexible substrate proximate said first end;
a second contact pad printed on said dielectric flexible substrate proximate said second end;
a connection line that extends said first length to create a single electrical pathway from said first contact pad to said second contact pad, wherein said first contact pad, said second contact pad and said connection line are all printed from a common conductive ink;
peel-away protective covers that cover said first contact pad and said second contact pad; and
an insulation layer applied over said peel-way protective covers and said connection line, wherein said peel-way protective covers and said connection line are interposed between said flexible substrate and said insulation layer, wherein said first contact pad and said second contact pad can be exposed by removal of said peel-away protective covers.
US Pat. No. 10,111,877

MODULATORS OF ANDROGEN SYNTHESIS

Tangent Reprofiling Limit...

1. A pharmaceutical composition comprising 0.1 mg to 20 mg of risperidone, 0.1 mg to 20 mg of a 9Z,11E conjugated Linoleic Acid, pharmaceutically-acceptable carriers and/or pharmaceutically-acceptable components, wherein there is a synergistic effect between the therapeutically effective amount of the risperidone and the therapeutically effective amount of a 9Z,11E conjugated Linoleic Acid; and wherein there is an inhibition in tumor growth in a cancer selected from the group consisting of pancreatic, prostate and lung cancer upon the administration of the pharmaceutical composition.
US Pat. No. 10,113,159

SUPPRESSION OF CANCER

Ipsen Bioinnovation Limit...

1. A polypeptide comprising:(i) a non-cytotoxic protease capable of cleaving a SNARE protein expressed in a cancer cell;
(ii) a targeting moiety capable of binding to a somatostatin receptor or a cortistatin receptor on the cancer cell;
(iii) a translocation domain capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the cancer cell; and
(iv) an intein, a destructive cleavage site, or a non-clostridial cleavage site;
wherein the polypeptide lacks the natural binding function of a clostridial neurotoxin HCC domain, which domain enables the clostridial neurotoxin to bind to one or more nerve terminals at the neuromuscular junction.
US Pat. No. 10,113,671

PROCESS FOR THE PRODUCTION OF A PIPE LINED WITH AN INLINER

EVONIK DEGUSSA GmbH, Ess...

1. A process for producing a pipe, comprising:introducing a thermoplastic inliner into a carrier pipe, the carrier pipe comprising an interior surface that has a shape and an exterior surface;
heating the exterior surface of the carrier pipe from the outside of the carrier pipe to a heating temperature higher than a crystallite melting point (Tm) of a moulding composition of an exterior surface of the inliner;
transferring the heat from the interior surface of the carrier pipe to the exterior surface of the inliner;
expanding the inliner radially in the carrier pipe so that the heated exterior surface of the inliner assumes the shape of the interior surface of the carrier pipe;
water cooling the inliner, thereby obtaining pipe comprising the carrier pipe and the thermoplastic inliner;
wherein
an external diameter of the inliner is at most 25% greater than an internal diameter of the carrier pipe, and
the cross section of the inliner is reduced by from 3 to 30%
the interior surface of the carrier pipe is a metal selected from the group consisting of steel, zinc and an alloy comprising aluminium, iron or zinc, and
the cross section of the inliner is reduced through exposure to an exterior force prior to being introduced into the carrier pipe.
US Pat. No. 10,111,879

ADRENOCEPTORS ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS

Cedars-Sinai Medical Cent...

1. A method for determining whether or not a non-motor symptom phase of idiopathic Parkinson's disease (iPD) is progressing in a human subject who has not been diagnosed with iPD based on motor symptoms, and who does not exhibit a motor symptom of iPD, but is exhibiting a non-motor symptom of iPD, comprising:performing an initial assay to measure cardiac uptake of iodine-123-metaiodobenzylguanidine (123I-MIBG) in the subject;
administering a composition comprising one or more adrenoceptor antagonist selected from the group consisting of: acebutolol, betaxolol, bisopropolol, bopindolol, carvedilol, metoprolol, oxprenolol, propranolol, and timolol;
subsequently performing an additional assay to measure cardiac uptake of 123I-MIBG in the subject, wherein it is determined iPD is progressing in the subject if the cardiac uptake of 123I-MIBG has decreased in the additional assay, compared to the initial assay; and wherein it is determined iPD is not progressing in the subject if the cardiac uptake of 123I-MIBG has not decreased in the additional assay, compared to the initial assay; and
continuing to administering the adrenoceptor antagonist if iPD is not progressing or providing an additional or alterative iPD treatment if iPD is progressing.
US Pat. No. 10,113,162

MODIFYING SOYBEAN OIL COMPOSITION THROUGH TARGETED KNOCKOUT OF THE FAD2-1A/1B GENES

CELLECTIS, Paris (FR)

1. A soybean plant, plant part, or plant cell comprising:(a) a deletion in each FAD2-1A allele, wherein said deletion in each FAD2-1A allele was induced by transcription activator-like (TAL) effector endonucleases targeted to SEQ ID NOS: 32 and 33, and
(b) a deletion in each FAD2-1B allele, wherein said deletion in each FAD2-1B allele is 23 bp in size, and wherein said deletion in each FAD2-1B allele was induced by TAL effector endonucleases targeted to SEQ ID NOS: 32 and 33,
wherein oil produced from said plant, plant part, or plant cell has increased oleic acid content and decreased linoleic acid content as compared to oil produced from a corresponding wild type soybean plant, plant part, or plant cell.
US Pat. No. 10,113,163

ADENOSINE NUCLEOBASE EDITORS AND USES THEREOF

President and Fellows of ...

1. An adenosine deaminase comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NOs: 1, 8, 9, 371, 372, 373, 374, or 375 with the exception of one or more substitutions at positions selected from the group consisting of amino acid residues corresponding to positions 8, 17, 18, 23, 34, 36, 45, 48, 51, 56, 59, 84, 85, 94, 95, 102, 104, 106, 107, 108, 110, 118, 123, 127, 138, 142, 146, 147, 149, 151, 152, 153, 154, 155, 156, and 157 of the amino acid sequence of SEQ ID NO: 1, wherein said adenosine deaminase deaminates adenine in deoxyribonucleic acid (DNA).
US Pat. No. 10,112,909

MORPHIC FORMS OF HEXADECYLOXYPROPYL-PHOSPHONATE ESTERS AND METHODS OF SYNTHESIS THEREOF

Chimerix, Inc., Durham, ...

1. A method of treating a viral infection in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically effective amount of morphic Form II of phosphonic acid, [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl) ethoxy]methyl]mono[3-(hexadecyloxy)propyl] ester.
US Pat. No. 10,113,165

MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE

ACADEMISCH ZIEKENHUIS LEI...

1. A method for inducing the skipping of exon 53 of the human dystrophin pre-mRNA in a subject with Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD), or a cell derived from the subject, said method comprising providing to said subject or said cell, an antisense oligonucleotide of 18 nucleotides consisting of the base sequence of the sequence CUGUUGCCUCCGGUUCUG (SEQ ID NO: 29), wherein said oligonucleotide induces exon 53 skipping in the human dystrophin pre-mRNA in the subject or a cell derived from the subject, said oligonucleotide comprising a modification selected from the group consisting of: 2?-O-methyl, 2?-O-methylphosphorothioate, a morpholine ring, a phosphorodiamidate linkage, a peptide nucleic acid and a locked nucleic acid.
US Pat. No. 10,112,910

CATALYSIS OF DIKETOPIPERAZINE SYNTHESIS

MannKind Corporation, We...

1. A method for the synthesis of N-protected 3,6-bis[4-aminoalkyl]-2,5-diketopiperazine comprising:a. a step for catalyzing a dehydrative cyclocondensation reaction of an amino acid having a free ?-amine group and a protected amine group, and
b. collecting the N-protected 3,6-bis[4-aminoalkyl]-2,5-diketopiperazine on a filter.
US Pat. No. 10,113,166

TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY

CuRNA, Inc., Miami, FL (...

1. A method of upregulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one single-stranded antisense oligonucleotide of 15 to 25 nucleotides in length or a siRNA oligonucleotide of 19 to 25 nucleotides in length wherein said at least one is 100% complementary with and specifically hybridizes to a 15 to 25 nucleotide region or, in the case of siRNA, to a 19 to 25 nucleotide non-overlapping sequence of SEQ ID NO: 2; thereby upregulating a function of and/or the expression of the Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro.
US Pat. No. 10,113,167

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

The Regents of the Univer...

1. A non-naturally occurring DNA-targeting RNA, or a nucleic acid encoding the non-naturally occurring DNA-targeting RNA, wherein the non-naturally occurring DNA-targeting RNA comprises:(a) a targeter-RNA comprising:
(i) a first nucleotide sequence that is complementary to a target sequence of a target DNA molecule, and
(ii) a second nucleotide sequence that hybridizes with an activator-RNA,
wherein the first and second nucleotide sequences are heterologous to one another; and
(b) the activator-RNA, which hybridizes with the second nucleotide sequence of the targeter-RNA to form a double-stranded RNA (dsRNA) duplex of a protein-binding segment, wherein the activator-RNA hybridizes with the targeter-RNA to form a total of 8 to 15 base pairs,
wherein the non-naturally occurring DNA-targeting RNA is capable of forming a complex with a Cas9 polypeptide and targeting the complex to the target sequence of the target DNA molecule.
US Pat. No. 10,113,168

RIBOZYME WITH TRNA SYNTHETASE ACTIVITY AND METHODS OF MANUFACTURING AND USING THE SAME

Purdue Reasearch Foundati...

1. An artificial ribozyme comprising:a T-box element comprising a 3?-terminus and a riboswitch element having a specifier loop for binding a cognate tRNA substrate with specificity; and
a flexizyme comprising SEQ ID NO: 2, which defines at least an active site for binding an unnatural amino acid, an acceptor end for base pairing to a terminus of a tRNA substrate, a nucleotide linker, and a P1 stem linked to the 3?-terminus of the T-box element,
wherein when the T-box element recognizes and preferentially binds the cognate tRNA substrate, the flexizyme can bind and aminoacylate the cognate tRNA substrate bound by the T-box element, and the active site of the flexizyme is not specific to a targeted unnatural amino acid.
US Pat. No. 10,111,887

MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN

Arstat, Inc., Flemington...

1. A method of contraception in a female, comprising:administering to the female daily, during a time period of 21 successive days, an oral combination drug formulation of a progestin and an estrogen,
wherein the oral combination drug formulation is administered in a biphasic dosing regimen comprising two phases, wherein the duration of one phase is 14 days and the duration of another phase is 7 days, wherein doses of each of the progestin and estrogen in the second phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the progestin and estrogen administered during the first phase of the regimen,
wherein the ratio of a daily dose of progestin to a daily dose of estrogen is maintained at a constant level during the entire dosing period, wherein the progestin in the oral combination drug formulation is norethindrone acetate, wherein the norethindrone acetate dose in the first phase is 1000 mcg, wherein the norethindrone acetate dose in the second phase is 1500 mcg,
wherein the estrogen in the oral combination drug formulation is ethinyl estradiol (EE), wherein the EE dose in the first phase is 20 mcg, wherein the EE dose in the second phase is 30 mcg and wherein the biphasic dosing regimen is followed by a time period of 7 days without progestin and estrogen administration.
US Pat. No. 10,111,888

INTRANASAL 0.15% AND 0.24% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER

ACERUS BIOPHARMA INC., O...

1. A method of treating a female for anorgasmia, said method comprising:(a) depositing an intranasal testosterone gel in an amount of between about 50 microliters and 150 microliters in each nasal cavity of each nostril of the female onto a mucosal membrane on an outer external nasal wall, opposite the nasal septum, preferably at about the middle to about the upper section of the outer external nasal wall and just under the cartilage section of the outer external nasal wall, to nasally deliver to the subject the intranasal testosterone gel to effectively treat the anorgasmia, wherein the testosterone gel comprises:
(i) about 0.15% testosterone by weight of the intranasal testosterone gel, wherein the testosterone has a particle size of greater than 10 ?m to prevent the testosterone particles from entering the respiratory tract following said nasal deposition; and
(ii) a pharmaceutically acceptable vehicle; and
(b) squeezing or rubbing the exterior of the nose of the female following said nasal deposition to contact the nasally deposited intranasal testosterone gel with the nasal septum mucosal membrane within the nasal cavity, so that at least a portion of the deposited intranasal testosterone gel remains in contact with the mucosal membranes on the outer nasal wall and the nasal septum within the nasal cavity for sustained release of the testosterone from the intranasal testosterone gel over dose life.
US Pat. No. 10,113,170

PREVENTING AND TREATING INFLAMMATORY SKIN DISEASES

TEL HASHOMER MEDICAL RESE...

1. A method of treating an inflammatory skin disease, condition or lesion in a human subject, comprising the step of administering to the subject a therapeutically effective amount of a composition comprising, as the only active ingredient, at least one sequence selected from mature miR-197 [SEQ ID NO: 8], mature miR-99a [SEQ ID NO: 17], or a combination thereof, and, optionally, at least one additional sequence selected from the group consisting of pre-miR-197 [SEQ ID NO: 9], pre-miR-99a [SEQ ID NO: 16], pre-miR-Let7c [SEQ ID NO: 12], mature miR-Let7c [SEQ ID NO: 13], pre-miR-125b-2 [SEQ ID NO: 14], mature miR-125b-2 [SEQ ID NO: 15], or any combination thereof.
US Pat. No. 10,111,889

USES OF GANAXOLONE

WISCONSIN ALUMNI RESEARCH...

1. A method of treating sleep disruptions due to absence epilepsy in a mammalian subject in need thereof, comprising administering ganaxolone to the mammalian subject in an amount of 0.2 to 2 mg/kg per dose, wherein the epilepsy is characterized by a deficit in tonic inhibition.
US Pat. No. 10,113,171

METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2

Carmel-Haifa University E...

1. A method for improving cortex or hippocampus dependent cognition in an Alzheimer disease patient or a patient with senility, comprising administering intracerebrally to said patient a nucleic acid molecule that reduces gene expression level of quinone reductase 2; a vector comprising said nucleic acid molecule; or a pharmaceutical composition comprising said nucleic acid molecule or said vector and a pharmaceutically acceptable carrier, wherein said quinone reductase 2 is a human quinone reductase 2 encoded by a nucleic acid sequence identified as SEQ ID NO:1.
US Pat. No. 10,112,916

HMF PRODUCTION FROM GLUCOSE IN IONIC LIQUID MEDIA

The Regents of the Univer...

1. A method of processing glucose, the method comprising:enzymatically converting glucose to fructose to yield a reaction mixture comprising the glucose and the fructose; and
after the enzymatic conversion, converting up to all of the fructose in the reaction mixture to 5-hydroxymethyl furfural by introducing a choline-containing ionic liquid to the reaction mixture.
US Pat. No. 10,111,891

COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE

ANTECIP BIOVENTURES II LL...

1. A method of delivering zoledronic acid to the blood of a human being, comprising: fasting the human being for at least four hours, followed by orally administering a dosage form containing about 30 mg to about 800 mg of the zoledronic acid in a salt form to the human being, followed by fasting the human being for at least one hour, wherein orally administering the dosage form to the human being results in a bioavailability of zoledronic acid that is about 1.5% to 3%.
US Pat. No. 10,113,173

PROMOTER EXHIBITING HIGH EXPRESSION ACTIVITY IN MORTIERELLA MICROORGANISMS

SUNTORY HOLDINGS LIMITED,...

1. A vector comprising a polynucleotide selected from:(a) a polynucleotide which contains any one nucleotide sequence selected from SEQ ID NO: 10, SEQ ID NO:11 and SEQ ID NO: 12; or
(b) a polynucleotide which has a nucleotide sequence sharing an identity of 90% or more with any one nucleotide sequence selected from SEQ ID NO: 10, SEQ ID NO:11 and SEQ ID NO: 12 and which shows promoter activity in cells of microorganisms belonging to the genus Mortierella.
US Pat. No. 10,113,943

MULTIPLE AGGRESSOR HAIR ASSESSMENT METHOD

Conopco, Inc., Englewood...

1. A method of comparatively evaluating the efficacy of a series of hair products, the method comprising, in any order, the steps of;applying each individual product or product system to an individual test hair switch;
subjecting each hair switch to the same regime of two or more aggressors, once a day for 4 or more days; and
assessing and comparing a condition of the switches that have been treated with the product or product system and subjected to said regime,wherein the individual product or product system is selected from the group consisting of shampoos, conditioners, and styling products, and the condition is a measurable physical feature or characteristic of the hair switches.
US Pat. No. 10,113,174

TOBACCO HAVING ALTERED LEAF PROPERTIES AND METHODS OF MAKING AND USING

Altria Client Services LL...

1. A variety of Nicotiana tabacum, the variety comprising plants having a mutation in an endogenous nucleic acid, the wild type endogenous nucleic acid encoding the PR50 sequence shown in SEQ ID NO:2, wherein plants having the mutation exhibit a reduced amount of nicotine relative to corresponding plants lacking the mutation, wherein leaf from plants having the mutation exhibit equal or better quality than leaf from corresponding plants lacking the mutation.
US Pat. No. 10,113,175

AP2 DOMAIN TRANSCRIPTION FACTOR ODP2 (OVULE DEVELOPMENT PROTEIN 2) AND METHODS OF USE

PIONEER HI-BRED INTERNATI...

1. A polynucleotide designed for expression in a plant selected from the group consisting of:(a) the polynucleotide encoding the amino acid sequence of SEQ ID NO:26;
(b) the polynucleotide encoding an amino acid sequence having at least 85% sequence identity to SEQ ID NO:26, wherein said polynucleotide encodes a polypeptide comprising two AP2 domains and that renders a plant cell embryogenic when expressed in the plant cell; and,
(c) the polynucleotide comprising a full length complement of the polynucleotide of (a)-(b);
wherein the polynucleotide is operably linked to a heterologous regulatory sequence.
US Pat. No. 10,111,894

DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE

ANTECIP BIOVENTURES II LL...

1. A method of treating arthritis, comprising: 1) fasting a human being for at least one hour, wherein the human being is suffering from arthritis, followed by 2) orally administering a dosage form comprising zoledronic acid to the human being, followed by 3) fasting the human being for at least one hour, wherein the zoledronic acid is administered to the human being in a manner that results in a bioavailability of zoledronic acid that is about 1.5% to about 2%.
US Pat. No. 10,112,150

POROUS GRAPHENE BASED COMPOSITE MEMBRANES FOR NANOFILTRATION, DESALINATION, AND PERVAPORATION

The Research Foundation f...

1. An article comprising:a nanofibrous scaffold;
at least a first layer of nanoporous graphene, nanoporous graphene oxide, or combinations thereof on at least a portion of a surface of the nanofibrous scaffold;
an additive selected from the group consisting of cross-linking agents and particles on an outer surface of the at least first layer of nanoporous graphene, nanoporous graphene oxide, or combinations thereof; and
at least a second layer of nanoporous graphene, nanoporous graphene oxide, or combinations thereof on at least a portion of the surface of the first layer of nanoporous graphene, nanoporous graphene oxide, or combinations thereof, such that the additive is between the first and second layers of nanoporous graphene, nanoporous graphene oxide, or combinations thereof.
US Pat. No. 10,113,176

ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USING SAME FOR INCREASING NITROGEN USE EFFICIENCY, YIELD, GROWTH RATE, VIGOR, BIOMASS, OIL CONTENT, AND/OR ABIOTIC STRESS TOLERANCE

Evogene Ltd., Rehovot (I...

1. A method of increasing nitrogen use efficiency, yield, biomass, growth rate, and/or abiotic stress tolerance of a plant as compared to a wild type plant of the same species which is grown under the same growth conditions, comprising expressing within the plant an exogenous polynucleotide comprising a nucleic acid sequence encoding the polypeptide set forth by SEQ ID NO: 672, thereby increasing the nitrogen use efficiency, yield, biomass, growth rate, and/or abiotic stress tolerance of the plant as compared to the wild type plant of the same species which is grown under the same growth conditions.
US Pat. No. 10,111,895

ANDROGEN EFFECTORS

Suzanne J. Paxton-Pierson...

1. A novel androgen effector method for treating diseases, these diseases selected from the list consisting of low androgenicity, low ergogenisis, male andropause, male climacteric, low anabolism, low metabolism, low catabolism, low libido in males, low muscle tone, low muscle development, erectile dysfunction, low facial hair, low libido in females and female menopause, the method consisting essentially of administering to a human or mammal subject in need thereof, a therapeutic composition or formulation consisting essentially of a therapeutically effective amount of the testosterone mimetic androgen receptor agonist protogracillin as an active principle, plus one or more excipients, said formulation optionally being combined with one or more agents selected from the list consisting of alpha-linolenic acid, alpha terpineol, 5-alpha reductase inhibitors, androstenedione, Angelica Tenuissima, arachidonic acid, artocarpin, beta-sitosterol, biochanin-A, boron, Castanea sativa, Cichorium intybus, coconut medium chain fatty acids, Cyperus rotundus, daidzein, dehydroepiandrosterone, dioscin, Dioscorea collettii, Dioscorea deltoidea, Dioscorea pseudojaponica, Dioscorea septemloba, Dioscorea zingiberensis, dutasteride, epicatechin, epigallocatechin, escins, estrogens, fenugreek, finasteride, flutamide, gamma linolenic acid (GLA), genistein, glabradin, glabrene, gracillin, icariin, leucoanthocyanidin, licochalcone A, linoleic acid, licorice, myristoleic acid, Nelumbo nucifera, octacosanol, oleic acid, Paeonia suffruticosa, palm fruit kernel, palmitic acid, palmitoleic acid, Panax japonicas, papaverine, Paris polyphylla, perennisosides, Perilla sikokiana, PDE5 inhibitors, phentolamine, phenoxybenzamine, phytosterols, Primula root, progesterone, prostaglandin E2, protodioscin, pumpkin seed extract, Pygium africanum, Quaiilla bark, Saponaria officinalis, S. Flavescens, secoisolariciresinol, Senega root, Serenoa repens, sildenafil, solasodine, stearic acid, testosterone, testosterone receptor agonists, unsaturated fatty acids vasoactive intestinal polypeptide or VIP, and Yucca via an effective dosage form in a pharmaceutically acceptable vehicle; wherein protogracillin is a direct androgen mimetic, xenoandrogen, or agonist of androgen receptor to provide androgenic effect, and whereby androgen receptor stimulation is increased by protogracillin.
US Pat. No. 10,113,177

YIELD IMPROVEMENT IN PLANTS

Koch Biological Solutions...

1. A transgenic plant having greater photosynthetic resource use efficiency than a control plant;wherein the transgenic plant comprises an exogenous recombinant polynucleotide comprising a photosynthetic tissue-enhanced promoter which is operably linked to a nucleic acid sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2;
wherein the promoter regulates expression of the polypeptide in a photosynthetic tissue to a level that is effective in conferring greater photosynthetic resource use efficiency in the transgenic plant relative to the control plant;
wherein the control plant does not comprise the recombinant polynucleotide; wherein the promoter does not regulate protein expression in a constitutive manner; and wherein expression of the polypeptide under the regulatory control of the promoter confers greater photosynthetic resource use efficiency in the transgenic plant relative to the control plant.
US Pat. No. 10,111,896

COMPOSITION COMPRISING A COMBINATION OF DNA METHYLATION INHIBITOR AND A VITAMIN D RECEPTOR AGONIST FOR THE TREATMENT OF DRUG RESISTANT CANCER OR FOR THE PREVENTION OF TUMOR RELAPSE

Institut National de la S...

1. A method of restoring or enhancing sensitivity to a chemotherapeutic agent in a patient suffering from hematopoietic malignancy, comprising simultaneously or sequentially administering to the patient a combination of:i. a DNA methylation inhibitor; and
ii. inecalcitol in an amount sufficient to restore or enhance sensitivity to the chemotherapeutic agent,
wherein said hematopoietic malignancy is acute myeloid leukemia,
wherein said acute myeloid leukemia is AML with normal karyotype with mutations in a gene selected from the group consisting of: FLT3, NPM1, KIT, CEBPA and MLL,
wherein said acute myeloid leukemia expresses mutated FLT3-ITD.
US Pat. No. 10,113,178

TRANSGENIC MAIZE EVENT MON 87419 AND METHODS OF USE THEREOF

Monsanto Technology LLC, ...

1. A recombinant DNA molecule comprising a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.
US Pat. No. 10,111,897

COMPOSITIONS AND METHODS FOR TREATING CANCER WITH JAK2 ACTIVITY

DUKE UNIVERSITY, Durham,...

1. A method of sensitizing a subject to a JAK2 inhibitor wherein the subject has developed resistance to a JAK2 inhibitor-based therapy and has at least one phosphorylated BAD- and/or activated BCL-XL protein, comprisingselecting a subject having developed a myeloproliferative neoplasm resistant to a JAK2 inhibitor-based therapy and has at least one phosphorylated BAD- or activated BCL-XL protein, and
administering to the selected subject a therapeutically effective amount of a BCL-XL protein inhibitor in combination with the JAK2 inhibitor, whereby the subject is sensitized to the JAK2 inhibitor.
US Pat. No. 10,112,923

1,2,4-TRIAZINE-4-AMINE DERIVATIVES

Heptares Therapeutics Lim...

1. A method of treatment of cancer, comprising administering an effective amount of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine, or a pharmaceutically acceptable salt or solvate, to a patient in need of such treatment, wherein the cancer is selected from the group consisting of prostate cancer, rectal cancer, renal cancer, ovarian cancer, endometrial cancer, thyroid cancer, pancreatic cancer, breast cancer, colon cancer, bladder cancer, brain cancer, glia cancer, melanoma cancer, pineal gland cancer, and lung cancer.
US Pat. No. 10,113,179

COMPOSITIONS AND METHODS FOR MODIFYING GENOMES

BENSON HILL BIOSYSTEMS, I...

1. A method of modifying a nucleotide sequence at a target site in the genome of a eukaryotic cell, said method comprising:introducing into said eukaryotic cell
(i) a DNA-targeting RNA, or a DNA polynucleotide encoding a DNA-targeting RNA, wherein the DNA-targeting RNA comprises: (a) a first segment comprising a nucleotide sequence that is complementary to a targeted sequence in the genome of said eukaryotic cell; and (b) a second segment that interacts with a Cpf1 polypeptide; and
(ii) a Cpf1 polypeptide, or a polynucleotide encoding a Cpf1 polypeptide, wherein the Cpf1 polypeptide comprises: (a) an RNA-binding portion that interacts with the DNA-targeting RNA; and (b) an activity portion that exhibits site-directed enzymatic activity,wherein said Cpf1 polypeptide has at least 95% identity with a sequence selected from the group consisting of: SEQ ID NOs: 125, 133, 138, 142, 143, and 173, and has Cpf1 nuclease activity, wherein said method modifies said nucleotide sequence at said target site, wherein said targeted sequence is located immediately 3? of a PAM site in the genome of said eukaryotic cell, wherein said Cpf1 polypeptide recognizes a TTTC PAM site, and wherein said genome of a eukaryotic cell is a nuclear, plastid, or mitochondrial genome.
US Pat. No. 10,111,898

ANTI-TUMOR COMPOSITIONS AND METHODS

PeptiMed, Inc., Madison,...

1. A composition for targeting tumor cells and inhibiting tumor growth by activating a subject's innate immune response, the composition comprising:an isolated double stranded oligonucleotide comprising a strand comprising the nucleic sequence of SEQ ID NO: 1 and a strand comprising the nucleic sequence of SEQ ID NO: 2;
a tumor cell-targeting moiety; and
a pharmaceutically acceptable salt thereof,
wherein said oligonucleotide activates a subject's innate immune response through activation of one or more toll-like receptors (“TLRs”).
US Pat. No. 10,112,154

POLYAMIDE-BASED WATER-TREATMENT SEPARATION MEMBRANE HAVING EXCELLENT DURABILITY, AND MANUFACTURING METHOD THEREFOR

LG CHEM, LTD., Seoul (KR...

1. A water treatment separation membrane comprising:a porous support;
a polyamide active layer formed on the porous support; and
a protective layer formed on the polyamide active layer, the protective layer comprising
polyvinyl pyrrolidone and a polymer including an amine group-containing compound, an epoxy group-containing compound and a fluoro-containing compound,
wherein a thickness of the protective layer is 0.5 nm to 1000 nm.
US Pat. No. 10,113,180

WHEAT STEM RUST RESISTANCE GENE

Commonwealth Scientific a...

1. A transgenic plant which has integrated into its genome a transgene comprising an exogenous polynucleotide encoding an Sr33 polypeptide, the polypeptide comprising an amino acid sequence which is at least 95% identical to the sequence set forth as SEQ ID NO: 1, wherein the polynucleotide is operably linked to a promoter capable of directing expression of the polynucleotide in a cell of the plant.
US Pat. No. 10,111,899

INTRAPULMONARY ADMINISTRATION OF POLYNUCLEOTIDE TOLL-LIKE RECEPTOR 9 AGONISTS FOR TREATING CANCER OF THE LUNG

Dynavax Technologies Corp...

1. An isolated polynucleotide, wherein the polynucleotide consists of SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9, and wherein at least one internucleotide linkage is a phosphorothioate linkage.
US Pat. No. 10,113,181

MANIPULATION OF DOMINANT MALE STERILITY

PIONEER HI-BRED INTERNATI...

1. A method of propagating wheat male sterile seeds, comprising:(a) emasculating a first wheat plant that is hemizygous for a GOF-MF (gain of function male fertility) gene which comprises a promoter operably linked to a polynucleotide encoding a male fertility polypeptide, and wherein the GOF-MF gene is linked to (1) a gene that disrupts the function and/or development of male-reproductive tissue and (2) a marker gene;
(b) pollinating the first wheat plant with pollen from a second wheat plant, wherein the second wheat plant is male fertile and comprises (1) a GOF-MF gene that when expressed in male tissue maintains fertility in said second plant, and (2) an exogenous LOF-mf (loss of function of male fertility) nucleic acid construct which comprises a promoter inverted repeat (pIR) sequence comprising at least a 20 nucleotide fragment that targets the promoter of the second plant's GOF-MF gene, wherein said GOF-MF gene is a wheat male fertility gene;
(c) harvesting seeds from the cross of part (b);
(d) selecting from among the harvested seeds of part (c) for those seeds comprising
(1) the GOF-MF gene linked to the gene that disrupts the function and/or development of male-reproductive tissue, and the marker gene; and
(2) the exogenous LOF-mf nucleic acid construct that targets the promoter of the second plant's GOF-MF gene,
wherein said seeds are hemizygous for the GOF-MF gene and the exogenous LOF-mf nucleic acid construct;
(e) planting the selected seeds of step (d) and allowing the plants grown from said seeds to self-pollinate, to produce progeny plants;
(f) screening the progeny plants produced by the selfed plants of step (e) and selecting those progeny plants homozygous for the exogenous LOF-mf nucleic acid construct;
(g) allowing the progeny plants selected in step (f) to self-pollinate to produce seeds;
(h) harvesting the seeds from step (g);
(i) planting the seeds harvested in step (h) that express the marker, and growing said seeds into plants;
(j) selecting the plants of step (i) that are
(1) hemizygous for the GOF-MF gene linked to the gene that disrupts the function and/or development of male-reproductive tissue, and the marker gene, and
(2) homozygous for the exogenous LOF-mf nucleic acid construct,
which selected plants can be used as maintainer plants to propagate a male-sterile inbred; and
(k) selecting the seeds from the plants of step (j) that do not express the marker, which seeds are homozygous for the exogenous LOF-mf nucleic acid construct, and which seeds produce male-sterile progeny.
US Pat. No. 10,111,900

?-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT

BIOTHERA, INC., Eagan, M...

1. A method of treating a subject having cancer, the method comprising administering soluble ?(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-?(1,3)-D-glucopyranose and an anti-PD-1 antibody.
US Pat. No. 10,113,182

SUBFAMILY E SIMIAN ADENOVIRUSES A1302, A1320, A1331 AND A1337 AND USES THEREOF

THE TRUSTEES OF THE UNIVE...

1. An adenovirus having a capsid comprising a hexon protein, a penton protein, and a fiber protein, wherein said hexon protein is the hexon protein of SAdV-A1302 with the amino acids 1 to 950 of SEQ ID NO: 9, said capsid encapsidating a heterologous nucleic acid comprising a gene operably linked to expression control sequences which direct at least one of transcription, translation, and expression of said gene in a host cell.
US Pat. No. 10,113,952

COMBINED VIBRATIONAL SPECTROSCOPY AND LASER INDUCED BREAKDOWN SPECTROSCOPY FOR IMPROVED MINERALOGICAL AND GEOCHEMICAL CHARACTERIZATION OF PETROLEUM SOURCE OR RESERVOIR ROCKS

Ingrain, Inc., Houston, ...

1. A method for determining mineralogy or geochemistry of a sample of a petroleum source or reservoir rock, comprising:a) obtaining one set of spectral data comprising vibrational spectral data on the sample;
b) obtaining another set of spectral data comprising LIBS spectral information on the sample, or a second sample of the petroleum source or reservoir rock that has a similar composition and structure;
c) obtaining mineralogical information or geochemical information on the sample using the two sets of spectral data
d) obtaining spatial information on the sample, using a vibrational spectroscopy measurement device or a LIBS measurement system; and
e) determining spatially resolved geochemical information for the sample using the mineralogical information or geochemical information and the spatial information.
US Pat. No. 10,116,002

PRODUCTION METHOD OF SOLID ELECTROLYTE

IDEMITSU KOSAN CO., LTD.,...

1. A method of producing a sulfide-based solid electrolyte comprising:contacting an alkali metal sulfide with a sulfur compound without pulverizing in a mixed solvent of an aromatic hydrocarbon solvent and a polar aprotic solvent, wherein:
the polar aprotic solvent is at least one of an ether solvent and a nitrile solvent, and a volume ratio of the aromatic hydrocarbon solvent to the polar aprotic solvent (aromatic hydrocarbon solvent: polar aprotic solvent) is 95:5 to 5:95.
US Pat. No. 10,111,901

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT

BIOTHERA, INC., Eagan, M...

1. A method of treating a subject having cancer, the method comprising administering soluble ?(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-?(1,3)-D-glucopyranose and an anti-PD-L1 antibody, wherein the anti-PD-L1 antibody is a non-complement-activating antibody.
US Pat. No. 10,113,183

ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE

The United States of Amer...

1. A recombinant nucleic acid molecule comprising a G6PC promoter/enhancer, a synthetic intron, and a G6PC coding region, wherein the nucleotide sequence of the recombinant nucleic acid molecule is at least 95% identical to nucleotides 182-4441 of SEQ ID NO: 1, and wherein the recombinant nucleic acid comprises at least one nucleotide substitution in the G6PC coding region that results in a coding change at residue 3, 54, 139, 196, 199, 242, 247, 292, 298, 301, 318, 324, 332, 347, 349, 350 or 353 of the human G6PC protein of SEQ ID NO: 4.
US Pat. No. 10,112,414

IMAGE RECORDING METHOD AND IMAGE RECORDED ARTICLE

Fujifilm Corporation, To...

1. An image recording method, comprising:subjecting a recording substrate to a surface treatment by irradiating an image recording surface of the recording substrate with light from excimer emission using a xenon gas, the recording substrate comprising an aggregate of non-absorbent or low absorbent fiber materials; and
applying an ink composition by an ink jet method onto the image recording surface of the recording substrate after the surface treatment,
wherein the fiber materials comprise at least one selected from the group consisting of polypropylene fibers and polyethylene fibers, and
wherein the aggregate is a non-woven fabric.
US Pat. No. 10,113,184

MICROBE TRANSFORMANT FOR WEIGHT LOSS AND LIPID REDUCTION, THE METHOD FOR CONSTRUCTING THE TRANSFORMANT, AND APPLICATION THEREOF

1. A transformant for weight loss and blood lipid reduction, wherein the transformant is obtained by replacing Lactococcus lactis (L. lactis) thyA gene with a codon-optimized human oxyntomodulin gene through homologous recombination.
US Pat. No. 10,115,490

METHOD FOR NUCLEAR WASTE STORAGE AND MONITORING

MWD-IP Holdings, LLC, Da...

1. A waste storage method, comprising:storing nuclear waste, including:
identifying a subterranean storage site location having a shale rock layer, the layer having an expected fluid overpressure in a range corresponding to greater than hydrostatic pressure to less than lithostatic pressure from overlying rock layers;
forming a storage borehole, with an end segment of the storage borehole located within the layer;
measuring the fluid pressure in the end segment of the storage borehole; and
if the measured fluid pressure in the end segment of the storage borehole is in the expected fluid overpressure range:
forming a monitoring borehole in the layer with an end segment of each of the monitoring boreholes being in a vicinity of the end segment of the storage borehole and
storing nuclear waste in the end segment of the storage borehole.
US Pat. No. 10,116,004

ELECTROLYTE FOR LITHIUM BATTERY FOR SOLID STATE DRIVE BACKUP POWER AND LITHIUM BATTERY FOR SOLID STATE DRIVE BACKUP POWER INCLUDING THE SAME

Samsung SDI Co., Ltd., Y...

1. An electrolyte for a lithium battery for solid state drive backup power, the electrolyte comprising:propylene carbonate;
ethylene carbonate;
diethyl carbonate; and
LiBF4, wherein:
the propylene carbonate is present in an amount of about 20 parts by weight to about 50 parts by weight, the ethylene carbonate is present in an amount of about 40 parts by weight to about 90 parts by weight, and the diethyl carbonate is present in an amount of about 1 part by weight to 10 parts by weight, based on 100 parts by weight of the combined propylene carbonate, ethylene carbonate, and diethylene carbonate, and
the electrolyte contains the LiBF4 in a molar concentration of about 0.8 M to about 1.2 M.
US Pat. No. 10,111,904

MICRON-SIZED GOLD, KIT COMPRISING SAID GOLD AND ITS USE AS A NON-TOXIC IMMUNE SUPPRESSOR

Berlock ApS, Aarhus C (D...

4. Medical device, for the treatment of inflammatory diseases, said medical device being obtainable by a method comprising the steps ofproviding a capped vial comprising solid micron-sized gold particles or gold flakes and at least one glass bead having a diameter of 3-8 mm,
injecting a liquid which is inert to the human body and which liquid is capable of maintaining the solid micron-sized gold particles or gold flakes in suspension for at least 1 minutes,
agitating the mixture of the solid micron-sized gold particles or gold flakes, the at least one glass bead and the injected liquid to provide a suspension, whereby the at least one glass beads facilitates efficient distribution of the solid micron-sized gold particles or gold flakes in the suspension,
aspirating the suspension into the syringe, whereby the medical device is provided said medical device being the solid micron-sized gold particles or gold flakes in suspension,
wherein the capped vial comprises between 5 and 10 mg of the solid micron-sized gold particles or gold flakes.
US Pat. No. 10,113,186

ALKENOL DEHYDRATASE VARIANTS

Global Bioenergies, Evry...

1. An alkenol dehydratase variant showing an improved activity in converting prenol into isoprene over the corresponding alkenol dehydratase from which it is derived, wherein the alkenol dehydratase variant is characterized in that it shows one or more substitutions, deletions and/or insertions in comparison to the corresponding sequence from which it is derived and wherein these substitutions, deletions and/or insertions occur at one or more of the positions corresponding to positions: 2, 7, 54, 55, 58, 88, 94, 105, 110, 111, 112, 113, 117, 139, 171, 177, 189, 203, 208, 231, 240, 257, 270, 291, 299, 305, 349, 350, 395 and 397 in the amino acid sequence at least 85% identical to the sequence of SEQ ID NO:1.
US Pat. No. 10,111,905

ANTIBACTERIAL PHARMACEUTICAL PREPARATION

1. A method of treating a bacterial infection in a patient in need thereof, comprising the following steps:contacting a whole blood sample with a vessel or container, wherein the vessel or container contains macroscopic particles from glass, plastic, corundum and or quartz and wherein during incubation the whole blood sample is in contact with the macroscopic particles;
incubating said whole blood sample in contact with said vessel or container, which results in an antibacterial agent in the form of a pharmaceutical preparation being produced, wherein the pharmaceutical preparation comprises exosomes that have been generated during the period of said incubation;
and
administering an effective amount of the pharmaceutical preparation to said patient who is in need of for treatment for bacterial infection, thereby treating the bacterial infection, wherein the exosomes of the pharmaceutical preparation interact with the bacteria to inhibit bacterial growth; said bacterial infection is caused by one or more bacteria selected from Salmonella.
US Pat. No. 10,113,187

METHODS AND SYSTEMS FOR REDUCING ONE OR MORE IMPURITIES AND/OR MOISTURE FROM GRAIN OIL, AND RELATED COMPOSITIONS

Poet Research, Inc., Sio...

1. A method of making a grain oil product comprising:providing a grain material comprising:
grain oil;
grain solids; and
one or more oligosaccharides and/or one or more polysaccharides;
converting at least a portion of the one or more oligosaccharides and/or one or more polysaccharides into one or more monosaccharides;
fermenting at least a portion of the one or more monosaccharides to form a fermentation product comprising the grain oil and a biochemical;
distilling the fermentation product to remove at least a portion of the biochemical from the fermentation product and form a whole stillage composition, wherein the whole stillage comprises the grain oil, the grain solids, and water;
separating the whole stillage into cake and thin stillage;
separating the thin stillage into syrup and a first grain oil product, wherein separating the thin stillage into syrup and a first grain oil product comprises:
concentrating the thin stillage to form an intermediate composition;
centrifugally separating at least a first portion of the intermediate composition into an aqueous component and an oil emulsion component; and
de-emulsifying the oil emulsion component to form the first grain oil product
providing at least a portion of the first grain oil product into a vessel; and
injecting a gas into the first grain oil product in the vessel in a manner to form gaseous bubbles in the first grain oil product and allow the gaseous bubbles to rise through at least a portion of the first grain oil product within the vessel and form a second grain oil product.
US Pat. No. 10,116,007

LEAD-ACID BATTERY SEPARATORS, ELECTRODES, BATTERIES, AND METHODS OF MANUFACTURE AND USE THEREOF

Daramic, LLC, Charlotte,...

1. A battery separator for a lead-acid battery with enhanced lead-acid energy storage performance comprises:a coating applied to a silica based material filled, polyolefinic lead acid battery separator, the coating comprising an engineered carbon material having a surface area (BET) of from 1500 to 3000 sqm/g;
wherein the battery separator has two surfaces, one surface which faces a positive electrode of a battery and one surface which faces a negative electrode of a battery and wherein the coating is placed on the surface which faces the negative electrode of the battery.
US Pat. No. 10,111,906

SERUM FRACTION OF PLATELET-RICH FIBRIN

Lacerta Technologies Inc....

1. A pharmaceutical preparation comprising a blood-derived serum product which is an isolated serum fraction of platelet rich fibrin (PRF) said blood-derived serum product being contained in an application device for administration of the serum fraction to an individual and being obtained by a method comprising the steps of:a. separating and removing the red blood cell fraction from a venous blood sample without the addition of an anticoagulant to provide a plasma;
b. clotting said plasma spontaneously by centrifugation carried out at 1000 to 5000 g to obtain a coagel of PRF and a supernatant, wherein in said method the centrifugation is carried out for 2 to 20 minutes;
c. pressing or squeezing the coagel to obtain a fluid fraction which comprises an activated platelet releasate from the coagel, wherein said isolated serum fraction of PRF contains the fluid fraction; and
d. providing the serum fraction in a pharmaceutical preparation which is contained in an application device for administration of the serum fraction to an individual, said serum fraction comprising a platelet releasate from activated platelets,wherein said isolated serum fraction of PRF comprises a reduced content of red blood cells, platelets or fibrinogen as compared to whole blood or a reduced content of fibrin as compared to said plasma, andwherein said serum fraction of PRF is depleted in PDGF-AB, PDGF-BB and TGF beta-1 as compared to said plasma or whole blood, and has a non-inflammatory blood factor profile, and a non-differentiating but cell proliferating profile on osteoblasts.
US Pat. No. 10,113,188

COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF FATTY ACID DERIVATIVES

Calysta, Inc., Menlo Par...

1. A alpha-proteobacterial methanotroph, comprising a heterologous nucleic acid molecule encoding a fatty acid converting enzyme, wherein the alpha-proteobacterial methanotroph comprising the heterologous nucleic acid molecule encoding the fatty acid converting enzyme is capable of converting a C1 substrate into a C8-C24 fatty aldehyde, fatty alcohol, fatty ester wax, a hydroxy fatty acid, dicarboxylic acid, or a combination thereof, and wherein the encoded fatty acid converting enzyme comprises:(a) a fatty acyl-CoA reductase capable of forming a fatty alcohol; or
(b) a fatty acyl-CoA reductase capable of forming a fatty aldehyde; or
(c) a carboxylic acid reductase; and
(d) a thioesterase; and/or
(e) an acyl-CoA synthetase.
US Pat. No. 10,111,395

MELON PLANTS WITH ENHANCED FRUIT YIELDS

1. A Cucumis melo plant or a part thereof carrying a loss of function mutation in the MELO3 C009603 gene, wherein the plant bears more than 12 fruit, said fruit being seedless.
US Pat. No. 10,111,907

METHODS OF TREATING ISCHEMIA

Fate Therapeutics, Inc., ...

1. A method of increasing stem or progenitor cell homing to an ischemic tissue or a tissue damaged by ischemia, comprising:(a) treating stem or progenitor cells ex vivo with a prostaglandin pathway agonist and a glucocorticoid; and
(b) administering a composition comprising the treated stem or progenitor cells to a subject having an ischemic tissue or a tissue damaged by ischemia.
US Pat. No. 10,112,933

METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS

BAYLOR COLLEGE OF MEDICIN...

1. A method of treating an individual that has fibrosis, comprising the step of providing to the individual an effective amount of one or more compositions selected from the group consisting of N-(1?,2-dihydroxy-1,2?-binaphthalen-4?-yl)-4-methoxybenzenesulfonamide, N-(1?,2-dihydroxy-1,2?-binaphthalen-4?-yl)-4-methoxybenzenesulfonamide, N-(3,1?-Dihydroxy-[1,2?]binaphthalenyl-4?-yl)-4-methoxy-benzenesulfonamide, N-(4,1?-Dihydroxy-[1,2?]binaphthalenyl-4?-yl)-4-methoxy-benzenesulfonamide, N-(5,1?-Dihydroxy-[1,2?]binaphthalenyl-4?-yl)-4-methoxy-benzenesulfonamide, N-(6,1?-Dihydroxy-[1,2?]binaphthalenyl-4?-yl)-4-methoxy-benzenesulfonamide, N-(7,1?-Dihydroxy-[1,2?]binaphthalenyl-4?-yl)-4-methoxy-benzenesulfonamide, N-(8,1?-Dihydroxy-[1,2?]binaphthalenyl-4?-yl)-4-methoxy-benzenesulfonamide, 4-Bromo-N-(1,6?-dihydroxy-[2,2?]binaphthalenyl-4-yl)-benzenesulfonamide, 4-Bromo-N-[4-hydroxy-3-(1H-[1,2,4]triazol-3-ylsulfanyl)-naphthalen-1-yl]-benzenesulfonamide, and a functional derivative thereof, wherein the fibrosis is not pulmonary fibrosis or myelofibrosis.
US Pat. No. 10,111,396

SOYBEAN VARIETY 5PZCY11

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PZCY11, representative seed of the variety having been deposited under ATCC Accession Number PTA-125128.
US Pat. No. 10,111,908

SPINAL DISC REGENERATIVE COMPOSITION AND METHOD OF MANUFACTURE AND USE

Vivex Biomedical, Inc., ...

1. A composition consisting of:(a) a syringe or injectable device which is capable of being inserted into a damaged disc to be treated; and
(b) a hydrated composition comprising hypothermically dried micronized nucleus pulposus in a fluid, produced by a method consisting of:
(i) providing normal human cadaveric intervertebral discs;
(ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral disc;
(iii) drying the nucleus pulposus;
(iv) micronizing the dried nucleus pulposus by pulverizing in a cryomill at low temperature into particles sized less than 400 microns;
(v) hypothermically drying the nucleus pulposus, wherein said hypothermically drying occurs during step (iii), and/or between steps (iii) and (iv), and/or during step (iv), and/or between steps (iv) and step (vi); and then
(vi) mixing the hypothermically dried micronized nucleus pulposus with a fluid, thereby producing the hydrated composition;
wherein the (b) hydrated composition is contained within the (a) syringe or injectable device, and
wherein the (b) hydrated composition has a viscosity which permits it to flow through a cannula.
US Pat. No. 10,113,190

METHOD FOR PRODUCING L-LEUCINE, L-VALINE, L-ISOLEUCINE, ?-KETOISOVALERATE, ?-KETO-BETA-METHYLVALERATE, OR ?-KETOISOCAPROATE USING RECOMBINANT CORYNEBACTERIA THAT CONTAIN THE ILVBN OPERON WHICH CAN BE INDUCED BY PROPIONATE

Evonik Degussa GmbH, Ess...

1. A process for the production of an L-amino acid selected from the group consisting of L-leucine, L-valine and L-isoleucine or of an ?-keto acid selected from the group consisting of ?-ketoisovalerate, ?-keto-methylvalerate and ?-ketoisocaproate, said process comprising:a) fermenting microorganisms of the genus Corynebacterium, wherein:
i) said microorganisms comprise, in replicable form, a polynucleotide with operator activity, the sequence of which is at least 85% identical to the sequence of position 1 to 121 of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 and to which the activator PrpR binds; and
ii) functionally downstream of the polynucleotide with operator activity, at the 3?-end, are a second polynucleotide having propionate- or 2-methylcitrate-inducible promoter activity; as well as genes ilvB and ilvN encoding for the subunits of an acetolactate synthase, and which regulates the transcription of the genes ilvBN as a function of the addition of the activator PrpR, in a medium;
b) during the fermenting of said microorganisms, there is a first phase (growth phase), which takes place without inducer, and a second phase during which propionate or 2-methylcitrate is added as an inducer, whereupon the desired L-amino acid or ?-keto acid is synthesized under conditions in which the desired L-amino acid or ?-keto acid is enriched in the medium and/or in the cells.
US Pat. No. 10,115,496

COMPOSITIONS FOR PREPARING ELECTRICALLY CONDUCTIVE COMPOSITES, COMPOSITES PREPARED THEREFROM, AND ELECTRONIC DEVICES INCLUDING THE SAME

Samsung Electronics Co., ...

1. A composition for an electrically conductive composite, comprising, based on a total weight of the composition:37 weight percent to 84 weight percent of an epoxy;
0.001 weight percent to about 1 weight percent of an electrically conductive filler; and
15 weight percent to about 38 weight percent of a thermoplastic resin,
wherein the thermoplastic resin is a liquid at about 25° C., is miscible with the epoxy, and forms a domain upon heat curing that is phase-separated from the epoxy and the electrically conductive filler,
wherein the thermoplastic polymer is carboxyl terminated butadiene acrylonitrile (CTBN),
wherein the electrically conductive filler is carbon nanotubes having no carboxyl group on a surface thereof.
US Pat. No. 10,111,397

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH249286

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH249286, produced by crossing a first plant of variety CV345806 with a second plant of variety CV197629, wherein representative seed of said varieties CV345806 and CV197629 have been deposited under ATCC Accession numbers PTA-124515 and PTA-120299, respectively.
US Pat. No. 10,111,909

THERAPEUTICS USING ADIPOSE CELLS AND CELL SECRETIONS

Cell Ideas Pty Ltd, Gord...

1. A method of alleviating pain in a mammalian subject, the method comprising,administering to the subject a pharmaceutical composition which comprises a combination of adipose tissue-derived cell secretions and multiply-passaged adherent cells from an adipose tissue-derived cell suspension,
wherein said adipose tissue-derived cell secretions are prepared by culturing multiply-passaged adherent progeny cells from an adipose tissue-derived cell suspension and harvesting supernatant from the cell culture after about 3 or more days,
said adherent progeny cells having a fibroblast-like appearance, and
wherein said combination has been cryopreserved.
US Pat. No. 10,113,191

MICROORGANISMS HAVING ENHANCED L-AMINO ACIDS PRODUCTIVITY AND PROCESS FOR PRODUCING L-AMINO ACIDS USING THE SAME

CJ CHEILJEDANG CORPORATIO...

1. A recombinant microorganism, wherein activity of at least one of adenosine deaminase comprising the amino acid sequence of SEQ ID NO: 14 and AMP nucleosidase comprising the amino acid sequence of SEQ ID NO: 16 is removed or decreased compared to that of a mother strain, wherein the recombinant microorganism belongs to the genus Escherichia and has enhanced producibility of an L-amino acid compared to that of the mother strain, wherein the L-amino acid is L-threonine or L-tryptophan, and wherein the recombinant microorganism does not contain chloramphenicol marker gene.
US Pat. No. 10,111,398

SOYBEAN CULTIVAR S170015

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170015, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124450.
US Pat. No. 10,113,192

METHOD FOR PRODUCING FRUCTOSE

ANNIKKI GMBH, Graz (AT)

1. A method for producing D-fructose from D-glucose, comprising:a) enzymatically oxidizing D-glucose to D-glucosone in a reaction vessel, and
b) enzymatically reducing the D-glucosone to D-fructose in reaction vessel,
wherein a redox cofactor is used in step b) and the redox cofactor is recycled by a cofactor regeneration system comprising a redox enzyme
wherein both enzymatic reaction of steps a) and b) are carried out in the reaction vessel and without the D-glucosone being isolated.
US Pat. No. 10,111,399

SOYBEAN CULTIVAR S170021

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170021, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124449.
US Pat. No. 10,111,911

COMPOSITIONS COMPRISING UNSATURATED FATTY ACIDS AND NITRIC OXIDE RELEASING COMPOUNDS AND USE THEREOF FOR ENHANCING COGNITIVE AND RELATED FUNCTIONS

Nestec S.A., Vevey (CH)

1. A method for enhancing cognitive function in an animal, the method comprising:identifying an animal in which enhancement of cognitive function is desired; and
administering a composition comprising effective amounts of citrulline and one or more unsaturated fatty acids (UFA) comprising docosahexaenoic acid (DHA) on a regular basis, wherein the administration on a regular basis of the composition for a time period results in enhanced cognitive function in the animal compared with an equivalent animal not administered the composition for an equivalent time period, the composition is administered in a daily dose comprising 0.5 g to 1.0 g of the DHA per day and 2.0 g to 10.0 g of the citrulline per day.
US Pat. No. 10,113,193

METHOD FOR OPTIMIZING THE ASSEMBLY AND PRODUCTION OF HETERO-MULTIMERIC PROTEIN COMPLEXES

NovImmune SA, Geneva (CH...

1. A method to increase production yield of a protein complex that comprises more than one polypeptide, the method comprising:(a) providing more than one nucleic acid molecules encoding the polypeptides in the protein complex, wherein the protein complex is a multispecific antibody or a bispecific antibody;
(b) introducing the nucleic acid molecule(s) into a cell;
(c) culturing the cell under conditions that allow for the expression of polypeptides in the protein complex; and
(d) decreasing expression of at least one of the polypeptides in the protein complex by modifying transcription rate, by modifying translation rate, by modifying mRNA stability, by modifying mRNA secondary structure, or by modifying any combination of these factors,
wherein the production yield of the protein complex is increased compared to when the expression of at least one of the polypeptides is not decreased.
US Pat. No. 10,111,912

HERBAL FORMULATIONS

MONTERO GIDA SANAYI VE TI...

1. A formulation for treating or preventing a respiratory tract disease comprising effective amounts of Propolis extract, Ginseng root extract and Zingiber officinale extract, wherein:the percentage amount of the Propolis extract based on the total volume of the formulation, is between 0.02% and 30% (w/v);
the percentage amount of the Ginseng root extract based on the total volume of the formulation, is between 0.05% and 60% (w/v);
the percentage amount of the Zingiber officinale extract based on the total volume of the formulation, is less than 30% (w/v); and wherein the formulation further comprises Glycyrrhiza glabra extract.
US Pat. No. 10,116,014

METHOD FOR MANUFACTURING AN ENERGY STORE

ROBERT BOSCH GMBH, Stutt...

1. A method for manufacturing an electrochemical energy store, the method comprising:providing a temperature control plate made of plastic, the temperature control plate at least partially including a heat-conducting material, and at least one contact area of the temperature control plate being plastically deformable;
bringing the at least one contact area into a deformable state by applying to the at least one contact area a pressure of greater than 0.1 N/cm2 for a time period of less than one hour;
while the at least one contact area is in the deformable state, applying a housing of at least one cell to the at least one contact area, and deforming the at least one contact area by the applying of the housing of the at least one cell to the at least one contact area to adapt a shape of the at least one contact area to the housing of the at least one cell, the applying of the housing of the at least one cell to the at least one contact area being a pressure-based application of the housing of the at least one cell to the at least one contact area in which the housing of the at least one cell is pressed into a material of the at least one contact area to deform the at least one contact area to adapt the at least one contact area to the shape of the housing of the at least one cell; and
hardening at least the at least one contact area of the temperature control plate after the deforming to set the at least one contact area in the adapted shape.
US Pat. No. 10,111,913

METHOD OF REDUCING THE LIKELIHOOD OF SKIN CANCER IN AN INDIVIDUAL HUMAN BEING

1. A method of reducing the likelihood of skin cancer in an individual human being, said method comprising: administering a therapeutically effective amount of a bacterial formulation comprising Nitrosomonas eutropha adapted to produce p53 said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto a region of an individual's skin.
US Pat. No. 10,111,914

COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS

California Institute of T...

1. A method for improving behavioral performance in a human subject, the method comprising:identifying a human subject who is at least 20 years old, having:
anxiety, autism spectrum disorder (ASD), or schizophrenia; and
an adult gut microbiota signature, said adult gut microbiota signature comprising at least 500 different species of microbes,
as a human subject in need of improving behavioral performance; and
administering to the human subject in need of improving behavioral performance an effective amount of one or more Bacteroides bacteria, thereby improving behavioral performance in the human subject.
US Pat. No. 10,113,196

PRENATAL PATERNITY TESTING USING MATERNAL BLOOD, FREE FLOATING FETAL DNA AND SNP GENOTYPING

Natera, Inc., San Carlos...

1. A method for establishing whether an alleged father is the biological father of a fetus that is gestating in a pregnant mother, the method comprising:obtaining genotypic measurements of single nucleotide polymorphism (SNP) alleles at a plurality of polymorphic loci on genetic material from the alleged father;
obtaining fetal and maternal genotypic measurements of SNP alleles at the plurality of polymorphic loci from genetic material isolated from a blood sample from the pregnant mother, wherein the blood sample comprises a mixture of free floating DNA of fetal origin and free floating DNA of maternal origin, wherein the obtaining of fetal and maternal genotypic measurements comprises amplifying the plurality of polymorphic loci from the free floating DNA of fetal origin and the free floating DNA of maternal origin together in a single reaction and measuring the genotypes of the SNP alleles in the amplified DNA by a technique selected from the group consisting of quantitative PCR, digital PCR, SNP microarrays, DNA microarrays, and sequencing;
determining a probability that the alleged father is the biological father of the fetus by calculating a test statistic for the alleged father and the fetus, wherein the test statistic for the alleged father and the fetus indicates a degree of genetic similarity between the alleged father and the fetus, and wherein the test statistic for the alleged father and the fetus is based on the genotypic measurements of SNP alleles made from genetic material from the alleged father and the genotypic measurements of SNP alleles made from genetic material isolated from the blood sample from the pregnant mother;
determining a distribution of test statistics for a plurality of unrelated individuals and the fetus, where each of the test statistics for the plurality of unrelated individuals and the fetus indicates a degree of genetic similarity between an individual unrelated to the fetus and the fetus, wherein the test statistic is based on genotypic measurements of SNP alleles made from genetic material from the unrelated individual and the genotypic measurements of SNP alleles made from genetic material isolated from the blood sample from the pregnant mother;
determining if the test statistic for the alleged father and the fetus belongs to the distribution of the test statistics for the plurality of unrelated individuals and the fetus; and
outputting that the alleged father is the biological father of the fetus if the test statistic for the alleged father and the fetus does not belong to the distribution of the test statistics for the plurality of unrelated individuals and the fetus.
US Pat. No. 10,111,915

METHOD TO TREAT FATTY LIVER DISEASE USING PARABACTEROIDES GOLDSTEINII

CHANG GUNG BIOTECHNOLOGY ...

1. A method for treating fatty liver disease in a subject on a high fat diet, comprising administering a composition comprising an effective amount of Parabacteroides goldsteinii bacterium, wherein the composition is orally administered to the subject for at least eight weeks.
US Pat. No. 10,111,916

COMPOSITIONS COMPRISING BACILLUS COAGULANS SPORES AND WHEY

Ganeden Biotech, Inc., M...

1. A composition which is in powdered or granular form, comprising Bacillus coagulans spores and a component obtained from the milk of a cow, sheep or goat, wherein the component is whey, and wherein said Bacillus coagulans is GBI-30, ATCC Designation Number PTA-6086.
US Pat. No. 10,113,198

GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF

Celera Corporation, San ...

1. A diagnostic method for identifying a human for administration of a therapeutic agent to reduce their increased risk for RF-positive rheumatoid arthritis, the method comprising:a) testing nucleic acid from said human for a polymorphism in gene PTPN22 as represented by position 101 of SEQ ID NO:36673 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to T at said position 101 of SEQ ID NO:36673 or A at said complement, wherein the nucleotide sequence of said oligonucleotide consists of a segment of at least 12 contiguous nucleotides of SEQ ID NO:36673 or its complement and includes said position 101;
b) detecting the presence of said T or said A;
c) identifying said human for administration of a therapeutic agent to reduce their increased risk for RF-positive rheumatoid arthritis due to the presence of said T or said A; and
d) administering a therapeutic agent suitable for prevention or treatment of RF-positive rheumatoid arthritis to said human.
US Pat. No. 10,111,917

METHOD FOR PREPARING PURIFIED EXTRACTS OF HARPAGOPHYTUM PROCUMBENS

NATUREX, Avignon (FR)

1. A method for preparing an extract of Harpagophytum procumbens for consumption as a food product, wherein said extract is in liquid or dry form, and wherein the extract has a harpagoside titer from 5% to 50% w/w, said method comprising:i.) preparing a crude extract of Harpagophytum procumbens by extracting roots of Harpagophytum procumbens with water and/or ethanol to provide an aqueous crude extract and plant material;
ii.) optionally filtering the plant material from the aqueous crude extract and removing the plant material from the crude aqueous extract to produce a crude filtered aqueous extract; and
iii.) purifying the crude aqueous extract or the crude filtered aqueous extract by liquid-liquid extraction using an ester organic solvent, wherein the crude aqueous extract or the crude filtered aqueous extract is extracted with the ester organic solvent, and the ester organic solvent provides an ester organic phase containing the extract of Harpagophytum procumbens.
US Pat. No. 10,112,173

ZEOLITE-BASED ADSORBENTS BASED ON ZEOLITE X WITH A LOW BINDER CONTENT AND A LOW OUTER SURFACE AREA, PROCESS FOR PREPARING THEM AND USES THEREOF

Arkema France, Colombes ...

1. An adsorbent comprising a zeolite-based phase and a non-zeolite-based phase, wherein said adsorbent:has an outer surface area of less than or equal to 30 m2·g?1,
a pore diameter distribution, determined by mercury intrusion according to standard ASTM D 4284-83 and expressed by the volume distribution dV/d log DHg, wherein DHg is the apparent pore diameter and V is the pore volume, the mode of which is between 100 nm and 250 nm, limits inclusive,
and the zeolite-based phase comprises at least one zeolite of FAU structure of X type.
US Pat. No. 10,113,199

BIOMARKERS FOR NON-HODGKIN LYMPHOMAS AND USES THEREOF

British Columbia Cancer A...

1. A method, comprising testing a sample from a human subject having B-cell non-Hodgkin lymphoma (NHL) for a mutation in Enhancer of Zeste Homolog 2 (EZH2), wherein the mutation in EZH2 is a non-synonymous substitution of Alanine (A) at position 682 (A682) of the wild-type EZH2 protein sequence and/or a non-synonymous substitution of Alanine (A) at position 692 (A692) of the wild-type EZH2 protein sequence.
US Pat. No. 10,111,918

METHOD OF PREPARING BIOLOGICALLY ACTIVE DERIVATIVES FROM CALOTROPIS GIGANTEA FLOWERS

KING SAUD UNIVERSITY, Ri...

1. A method of preparing biologically active derivatives from Calotropis gigantea flowers, comprising:obtaining Calotropis gigantea flowers;
drying the Calotropis gigantea flowers to provide dried flowers;
soaking the dried flowers in an oil to provide oil-soaked flowers; and
burning the oil-soaked flowers at a temperature of at least about 600° C., to provide flower ash, the flower ash including biologically active derivatives.
US Pat. No. 10,111,919

COSMETIC COMPOSITIONS

Mary Kay Inc., Addison, ...

1. A method for treating pruritus in a subject in need thereof comprising topically applying to the skin of said subject a composition that includes effective amounts of an extract from Echinacea purpurea and an extract from Silybum marianum fruit,wherein topical application of the composition activates human cannabinoid receptor type 2 and inhibits fatty acid amide hydrolase activity in said skin and, thereby, treats the pruritus.
US Pat. No. 10,113,201

METHODS AND COMPOSITIONS FOR DIAGNOSIS OF GLIOBLASTOMA OR A SUBTYPE THEREOF

The Wistar Institute of A...

1. A kit consisting of ligands that quantitatively detect or identify every one of 121 target isoforms of a glioblastoma (GBM) isoform transcript signature SEQ ID Nos: 1-78 and 95-137, wherein each ligand is a nucleotide or oligonucleotide sequence that binds or hybridizes to a single said target isoform, wherein each ligand is 17 to 30 bases in length, and wherein at least one ligand is covalently joined to a detectable diagnostic label capable of generating a measurable signal; and optionally at least one assay component selected from a substrate for immobilization, a substrate for an enzymatic label, a reagent for conducting an RNA-based assay or an RT-qPCR assay, and computer software.
US Pat. No. 10,111,920

SALT-FREE MISO PRODUCTION METHOD, SALT-FREE MISO, HEPATIC FUNCTION IMPROVEMENT AGENT, AND HYPERTENSION IMPROVEMENT AGENT

MARUZEN PHARMACEUTICALS C...

1. A method of producing salt-free product of reaction of steamed soybeans with koji culture, comprising the step of fermenting steamed soybeans and koji culture under applied heat and pressure,wherein the applied heat and pressure conditions are a pressure of 50 to 80 MPa and a temperature of 50 to 60° C., and
the length of the fermenting step is one to five days.
US Pat. No. 10,112,176

SURFACE-MODIFIED SUPER ABSORBENT RESIN AND METHOD FOR PREPARING SAME

LG Chem, Ltd., (KR)

1. A surface-modified superabsorbent polymer, having a surface modified with a water-soluble polyvalent cationic salt and a polycarbonic acid-based copolymer.
US Pat. No. 10,113,202

METHOD FOR DETERMINING THE METHYLATION STATUS OF THE PROMOTER REGION OF THE TWIST1 GENE IN GENOMIC DNA FROM BLADDER CELLS

MDxHealth SA, Herstal (B...

1. A method comprising:(a) treating genomic DNA isolated from bladder cells in a urine sample with a reagent which selectively modifies unmethylated cytosine residues in DNA contained in the sample to produce detectable modified residues but which does not modify methylated cytosine residues;
(b) amplifying the treated genomic DNA with primers that bind to the promoter region of the TWIST1 gene to produce an amplicon; and
(c) detecting the amplicon to determine the methylation status of the promoter region of the TWIST1 gene;
wherein the amplicon is detected by contacting the amplicon with a probe, and:
(i) the probe comprises the nucleotide sequence of SEQ ID NO:24; or
(ii) the amplicon comprises the probe binding site for SEQ ID NO:24.
US Pat. No. 10,111,921

REGULATION OF BRAIN BIOGENIC AMINES ASSOCIATED WITH DEPRESSION BY A FORMULATION FROM BOTANICAL SOURCE

GoVind Prasad Dubey, Utt...

1. An anti-depressant tablet or capsule consisting essentially of therapeutically effective amounts of Nyctanthes arbor-tristis extract, Ocimum tenuiflorum extract, and Hippophae salicifolia extract.
US Pat. No. 10,113,203

DIAGNOSIS KIT AND CHIP FOR BLADDER CANCER USING BLADDER CANCER SPECIFIC METHYLATION MARKER GENE

GENOMICTREE, INC., Daeje...

1. A method for detecting CpG methylation of PENK (proenkephalin gene), the method comprising the steps of:(a) isolating a genomic DNA from a clinical sample;
(b) treating the genomic DNA from step (a) with bisulfite; and
(c) determining hypermethylation of the CpG of the PENK gene in the bisulfite-treated genomic DNA from step (b) by using primer(s) to amplify a methylated CpG of the bisulfite-treated PENK gene, wherein the primer(s) for amplifying a methylated CpG of PENK comprises sequence(s) selected from the group consisting of SEQ ID NOs: 43-44, 46-185, 187-298, 300-341, 343-468, 470-579, 581-704, 706-841, 843-976, 978-1097, 1099-1210, 1212-1221.
US Pat. No. 10,111,922

PREPARATION METHOD OF TEA WATER, AND TEA WATER OBTAINED THEREBY

AMOREPACIFIC CORPORATION,...

1. A method for preparing aged tea water, comprising:deactivating enzymes of raw tea leaves by subjecting the raw tea leaves to steaming, and extracting juice therefrom to obtain tea juice, wherein the raw tea leaves are non-processed tea leaves;
removing ions from the tea juice to obtain tea water; and
aging the tea water at 0-120° C. for 12-24 hours,
wherein the aged tea water comprises; linalool in an amount of 5 ?g/mL or less; hexanol in an amount of 0.2 ?g/mL or less; and/or z-3-hexenol an amount of 0.2 ?g/mL or less.
US Pat. No. 10,113,204

METHODS AND MATERIALS FOR DETECTING VIRAL OR MICROBIAL INFECTIONS

Cascade Biosystems, Inc.,...

1. A kit for assessing a mammal for an infection, said kit comprising:(a) probe nucleic acid comprising a nucleotide sequence complementary to a sequence of a target nucleic acid present within a microorganism or virus capable of infecting said mammal, wherein at least a portion of said target nucleic acid is capable of hybridizing to at least a portion of said probe nucleic acid to form a double-stranded portion of nucleic acid comprising a restriction endonuclease cut site, wherein said probe nucleic acid comprises a restriction endonuclease, and
(b) signal expansion nucleic acid comprising an amplifying restriction endonuclease, a label, and a double-stranded portion of nucleic acid comprising a restriction endonuclease cut site of said restriction endonuclease of said probe nucleic acid.
US Pat. No. 10,111,923

COMPOSITIONS COMPRISING CYCLOCARYA PALIURUS EXTRACT AND PREPARATION METHOD AND USES THEREOF

INFINITUS (CHINA) COMPANY...

1. A method for preparing an herbal extract composition comprising an extract of Cyclocarya paliurus, Puerariae lobatae Radix and Polygonati odorati Rhizoma, wherein the method comprises:i) providing a mixture of Cyclocarya paliurus leaves, Puerariae lobatae Radix and Polygonati odorati Rhizoma, wherein said mixture comprises about 30-40% (w) Cyclocarya paliurus leaves, about 30-40% (w) Puerariae Radix and about 20-30% (w) Polygonati odorati Rhizoma;
ii) extracting said mixture with water to obtain an aqueous extract;
iii) concentrating the aqueous extract to obtain a concentrated mixture;
iv) obtaining a liquid portion of said concentrated mixture; and
v) drying said liquid portion to produce an herbal extract composition.
US Pat. No. 10,113,205

COMPOSITIONS TO DETECT SEASONAL H1 INFLUENZA A VIRUS NUCLEIC ACIDS

GEN-PROBE INCORPORATED, ...

1. A composition comprising:at least first and second seasonal H1 influenza A-specific amplification primers, wherein the first primer comprises a H1 influenza A-specific sequence consisting of SEQ ID NO:72 and the second primer comprises a H1 influenza A-specific sequence consisting of SEQ ID:73; and
a seasonal H1 influenza A-specific oligonucleotide detection probe having a H1 influenza A-specific sequence of at least 18 contiguous nucleotides, wherein said detection probe is complementary to a H1 influenza A nucleic acid sequence that is amplifiable by the first and second primers, and wherein said detection probe comprises at least a first detectable label operably linked to said oligonucleotide detection probe.
US Pat. No. 10,111,924

DIETARY SUPPLEMENT FOR THE TREATMENT OF ACID REFLUX AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD/GERD)

KFSU LTD, Queensland (AU...

1. A method of treating acid reflux in a human in need thereof consisting essentially of administering therapeutically effective amounts of sugarcane fiber and a component selected from the group consisting of psyllium and bran to effectively treat the acid reflux in the human in need thereof.
US Pat. No. 10,112,180

CERIA-ZIRCONIA COMPOSITE OXIDE, METHOD FOR PRODUCING THE SAME, AND CATALYST FOR PURIFYING EXHAUST GAS USING THE CERIA-ZIRCONIA COMPOSITE OXIDE

TOYOTA JIDOSHA KABUSHIKI ...

1. A ceria-zirconia composite oxide containing a composite oxide of ceria and zirconia, comprisinglanthanum, wherein
a ratio of a total content of lanthanum to a total content of cerium and zirconium in the ceria-zirconia composite oxide is 0.25 atomic % to 2.5 atomic %,
a content of lanthanum present in near-surface regions accounts for 90 atomic % or more of the total content of lanthanum, the near-surface regions being at a distance of less than 50 nm from surfaces of primary particles of the ceria-zirconia composite oxide,
a content ratio of cerium to zirconium in the ceria-zirconia composite oxide is in a range from 43:57 to 48:52 by molar ratio,
an average particle size of the primary particles of the ceria-zirconia composite oxide is 2.2 ?m to 4.5 ?m, and
an intensity ratio I(14/29) of a diffraction line at 2?=14.5° to a diffraction line at 2?=29° and an intensity ratio I(28/29) of a diffraction line at 2?=28.5° to the diffraction line at 2?=29° respectively satisfy the following conditions:
I(14/29)?0.02; and
I(28/29)?0.08,
wherein the intensity ratio I(14/29) and the intensity ratio I(28/29) are calculated from an X-ray diffraction pattern of the ceria-zirconia composite oxide, the X-ray diffraction pattern being obtained by an X-ray diffraction measurement using CuK? after heating the ceria-zirconia composite oxide under a temperature condition of 1100° C. in air for 5 hours.
US Pat. No. 10,113,206

METHODS, COMPOSITIONS, AND KITS FOR DETERMINING HUMAN IMMUNODEFICIENCY VIRUS (HIV)

Grifols Therapeutics Inc....

1. A method for amplifying an HIV-1 group M, HIV-1 group O, and HIV-2 target sequence, the method comprising:performing a single multiplex real time PCR with the HIV-1 group M, HIV-1 group O, and HIV-2 target sequences as templates, wherein performing comprises providing the PCR with forward primer and reverse primer pairs, wherein the forward primer and the reverse primer pairs consist of, respectively, the sequences as set forth in SEQ ID NO:1 and SEQ ID NO:2; SEQ ID NO:3 and SEQ ID NO:4; and SEQ ID NO:5 and SEQ ID NO:6.
US Pat. No. 10,111,925

FORMULATIONS COMPRISING PLANT EXTRACTS

MONTERO GIDA SANAYI VE TI...

1. A formulation for treating or preventing a respiratory tract disease comprising effective amounts of a Hedera helix extract, a Pelargonium sidoides extract, and a Zingiber officinale extract, wherein the percentage amount of the Hedera helix extract based on the total volume of the formulation is between 0.05% and 20% (w/v); the percentage amount of the Pelargonium sidoides extract based on the total volume of the formulation is between 0.05% and 30% (w/v); and the percentage amount of the Zingiber officinale extract based on the total volume of the formulation is between 0.05% and 30% (w/v).
US Pat. No. 10,112,181

CATALYST FOR PURIFICATION OF EXHAUST GAS, METHOD FOR PRODUCING THE SAME, AND METHOD FOR PURIFICATION OF EXHAUST GAS USING THE SAME

KABUSHIKI KAISHA TOYOTA C...

1. A catalyst for purification of exhaust gas, comprising:a substrate; and
a catalyst coat layer which is formed on a surface of the substrate and which comprises catalyst particles, wherein
the catalyst coat layer has an average thickness in a range of 25 to 160 ?m, and a void fraction in a range of 50 to 80% by volume as measured by a weight-in-water method,
0.5 to 50% by volume of all voids in the catalyst coat layer consist of high-aspect ratio pores which have equivalent circle diameters in a range of 2 to 50 ?m in a cross-sectional image of a cross-section of the catalyst coat layer which the cross-section is perpendicular to a flow direction of exhaust gas in the substrate, and which have aspect ratios of 5 or higher, and
the high-aspect ratio pores have an average aspect ratio in a range of 10 to 50.
US Pat. No. 10,113,207

METHODS AND COMPOSITIONS FOR TARGETED SINGLE-STRANDED CLEAVAGE AND TARGETED INTEGRATION

Sangamo Therapeutics, Inc...

1. A method of modifying a genomic sequence in a cell, the method comprising introducing a polynucleotide encoding an artificial nuclease into the cell, the artificial nuclease comprising(i) first and second cleavage domains from an endonuclease, wherein the first cleavage domain is catalytically inactive and the second cleavage domain is catalytically active; and
(ii) a DNA-binding molecule that is heterologous to the first and second cleavage domains, and further wherein the DNA-binding molecule of the nuclease binds to a target sequence in a double-stranded genome and the nuclease induces a site-specific single-stranded break at or near the target sequence in the double-stranded genome such that the genomic sequence is modified.
US Pat. No. 10,111,926

SELECTIVELY TARGETED ANTIMICROBIAL PEPTIDES AND THE USE THEREOF

The Regents of the Univer...

1. A method of reducing the ratio of living Streptococcus mutans to total streptococci in a biofilm, said method comprising contacting said Streptococcus mutans with an amount of a construct effective to kill an Streptococcus mutans, wherein said construct comprises a targeting peptide that binds Streptococcus mutans attached to an antimicrobial peptide, wherein the amino acid sequence of said targeting peptide consists of a fragment of the competence stimulating peptide (CSP) ranging in length from 8 to 20 amino acids.
US Pat. No. 10,112,182

CATALYTIC ADSORBENT FOR THE CAPTURE OF ARSENIC AND THE SELECTIVE HYDRODESULFURIZATION OF GASOLINES

IFP ENERGIES NOUVELLES, ...

1. A catalytic adsorbent comprising at least cobalt and molybdenum deposited on a porous substrate in which the content of cobalt, expressed in terms of CoO oxide, is between 20 and 25% by weight relative to the total weight of said adsorbent, and the content of molybdenum, expressed in terms of MoO3 oxide, is between 3 and 30% by weight relative to the total weight of said adsorbent and in which the Co/Mo molar ratio is between 1 and 6, and wherein the cobalt and molybdenum are in part in sulfur form, the content and ratios of Co and Mo being determined before adding sulfur to put them part in sulfur form.
US Pat. No. 10,113,208

COMBINATORIAL METABOLIC ENGINEERING OF SACCHAROMYCES CEREVISIAE FOR TERMINAL ALKENE PRODUCTION

National University of Si...

1. A modified Saccharomyces cerevisiae yeast wherein the modification comprises:insertion of at least one heterologous fatty acid decarboxylase gene encoding a fatty acid decarboxylase that synthesizes terminal alkenes selected from 1-undecene, 1-tridecene, 1-pentadecene, 1-heptadecene or 1-nonadecene,
deletion of fatty acyl-Coenzyme A synthetases, FAA1 and FAA4,
overexpression of porphobilinogen deaminase, HEM3, and
triple-deletion of catalase T, CTT1, catalase A CTA1 and cytochrome c peroxidase, CCP1.
US Pat. No. 10,111,927

PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES

The United States of Amer...

1. A Pseudomonas exotoxin A (PE) comprising a PE amino acid sequence, wherein one or more of amino acid residues selected from the group consisting of E420, D463, Y481, L516, R563, D581, and D589 as defined by reference to SEQ ID NO: 1 are, independently, substituted, with the proviso that when the amino acid residue at position 516 is substituted with alanine, at least one of amino acid residues E420, D463, Y481, R563, D581, and D589 is substituted,wherein the PE has a further substitution of one or more amino acid residues within one or more B cell epitopes, and the further substitution of one or more amino acid residues within one or more B-cell epitopes is a substitution of independently, one or more of amino acid residues selected from the group consisting of E285, P290, R313, N314, P319, D324, E327, E331, Q332, D403, D406, R412, R427, E431, R432, R458, D461, R467, R490, R505, R513, E522, R538, E548, R551, R576, Q592, and L597 as defined by reference to SEQ ID NO: 1, and
wherein the PE optionally has (i) a further substitution of one or more amino acid residues within one or more T-cell epitopes, (ii) a deletion of one or more continuous amino acid residues of residues 1-273 and 285-394 as defined by SEQ ID NO: 1, or (iii) a combination of (i) and (ii).
US Pat. No. 10,111,928

PULSED INTRODUCTION OF LOW-DOSE RANKL AS A THERAPY FOR OSTEOGENESIS IMPERFECTA

Saint Louis University, ...

1. A method for treating osteogenesis imperfecta in a patient, the method comprising:providing said patient a RANK agonist being of:
sufficient amount to induce osteoclasts of said patient to produce FoxP3+ CD8 T-cells (TcREG); and
insufficient amount to activate enough of said osteoclasts to create new bone loss in said patient;
repeating said providing according to a fixed schedule so as to provide said RANK agonist to said patient at pulsed intervals, said patient having as a result of said fixed schedule increased bone mass compared to a patient not on said fixed schedule.
US Pat. No. 10,112,184

ALUMINOSILICATE AEI ZEOLITE PREPARATION

Johnson Matthey Public Li...

andb. reacting the reaction mixture at an elevated temperature for a period of time sufficient to form zeolite crystals having an AEI framework and a silica-to-alumina ratio (SAR) of about 10 to about 30, wherein the reacting step, prior to removal of SDAs from the zeolite crystals, has a relative yield based on the weight of the AEI to the weight of the reaction mixture of ?about 5%.
US Pat. No. 10,111,929

GROWTH HORMONE RELEASING FACTOR ANALOGS AND USES

EZ IP, LLC, Castle Rock,...

1. A growth hormone releasing factor (GHRF) analog comprising a sequence of Xaa1-D-2-Nal-Trp-His-Trp-D-Phe-Xaa2, wherein Xaa1 is an amino acid residue selected from D-Ala, D-Val and Gly and Xaa2 is an amino acid residue selected from Lys and Arg, or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,112,185

CATALYST AND MANUFACTURING METHOD OF CATALYST

HYUNDAI MOTOR COMPANY, S...

1. A catalyst manufacturing method comprising:preparing UZM-35 zeolite;
manufacturing ion-containing UZM-35 zeolite by exchanging ions in the UZM-35 zeolite; and
manufacturing metal-containing UZM-35 zeolite by exchanging copper (Cu) ions or iron (Fe) ions in the ion-containing UZM-35 zeolite.
US Pat. No. 10,111,930

TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY

Shire-NPS Pharmaceuticals...

1. A method for treating an adult human patient with short bowel syndrome who is dependent on parenteral nutrition and who presents with colon-in-continuity with remnant small intestine, said method comprising administering to the patient [Gly2]hGLP-2 using a dosing regimen effective to reduce the dependency on parenteral nutrition by the patient.
US Pat. No. 10,112,186

BETA MOLECULAR SIEVE, PREPARATION METHOD THEREFOR AND HYDROGENATION CATALYST CONTAINING SAME

FUSHUN RESEARCH INSTITUTE...

1. A ? zeolite having a SiO2/Al2O3 molar ratio of 30-150, non-skeleton aluminum of not more than 2% based on the total aluminum, Si(OAl)-coordinated silicon atom of not less than 95% based on silicon atom in a skeleton structure.
US Pat. No. 10,111,931

TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY

Shire-NPS Pharmaceuticals...

1. A method of treating an adult human patient having short bowel syndrome with at least 25% colon-in-continuity with remnant small intestine and who receives an amount of parenteral nutrition each week, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to reduce or eliminate said weekly amount of parenteral nutrition received by said patient.
US Pat. No. 10,112,187

HIGH STRENGTH SAPO-34 MICROSPHERE CATALYST, METHOD FOR PREPARING SAME, AND METHOD FOR PREPARING LIGHT OLEFINS USING SAME

KOREA RESEARCH INSTITUTE ...

1. A method for preparing a SAPO-34 microsphere catalyst which is applied to a methanol-to-olefin (MTO) reaction, comprising:spray drying a mixed slurry comprising 100 parts by weight of a crystallized undried silicoaluminophosphate-34 (SAPO-34) slurry, 50-300 parts by weight of a binder and 0.5-5 parts by weight of an additive to prepare microspheres; and
firing the microspheres, wherein the binder consists of one or more selected from an alumina sol and a silica sol, and wherein the additive consists of one or two or more selected from hydrochloric acid, nitric acid, acetic acid, and formic acid,
wherein the crystallized undried SAPO-34 slurry is prepared by hydrothermally synthesizing a mixed synthetic gel in which a synthetic gel comprising an aluminum phosphate gel, a first organic template and a solvent; and a silica-dissolving solution comprising a silica precursor, a second organic template and a solvent are mixed,
wherein the mixed slurry comprises kaolin as a matrix in range of 13.3-67 parts by weight based on 100 parts by weight of the SAPO-34 slurry,
wherein the solvent comprises one or two selected from water and alcohol in a molar ratio of 10 to 60 based on 1 mole of an alumina precursor (based on Al2O3),
wherein the crystallized undried SAPO-34 slurry includes SAPO-34 with average crystal size of less than 1 ?m,
wherein the hydrothermal synthesis is performed by putting the mixed synthetic gel into an autoclave, maturing the mixed synthetic gel while being stirred at 20° C. to 120° C. for 0.5 hr to 24 hr and stirring the mixed synthetic gel at 150° C. to 200° C. for 5 hr to 48 hr to perform crystallization,
wherein a molar ratio calculated by the first organic template/the second organic template is 0.5 to 2.0,
wherein the SAPO-34 microsphere catalyst is used in circulating-fluidized bed reactor for preparing light olefins.
US Pat. No. 10,113,213

PROCESSING AND APPLICATION OF A PURIFICATION SYSTEM FOR A NEW ALTERNATIVE SOURCE OF ENERGY

University of Bisha, Bis...

1. A method of producing at least one metal from a gold ore and oil and/or ethanol from algae, the method comprising:(a) treating a first salt water stream having a first salt concentration X,
wherein the treating is carried out with at least one of electrodialysis reversal, reverse osmosis, and mechanical vapor compression in a first water purification system to form: (i) a first purified water stream having a second salt concentration Y lower than X, and (ii) a first saline water stream having a third salt concentration Z higher than X,
(b) treating the gold ore with the first purified water stream to separate gold from the gold ore and form a waste water comprising metal ions in a gold mining production system,
(c) treating the first saline water stream in a second water purification system connected to the first water purification system to form a second saline water stream and a second purified water stream,
wherein the second purified water stream has a fourth salt concentration A lower than Z, and the second saline water stream has a fifth salt concentration B higher than Z,
(d) feeding the second saline water stream to a bioreactor containing algae to form a first algae biomass in the saline water of the second saline water stream,
(e) feeding the first algae biomass to an algae growth and harvesting chamber to grow the first algae biomass and form a concentrated algae biomass,
(f) feeding the concentrated algae biomass to a waste water processing unit,
wherein the concentrated algae biomass forms a first algae mat in the waste water processing unit, wherein the first algae mat comprises 10-200 layers of algae and each layer of algae has a length and/or a width of 50-500 cm and a depth of 0.5-50 cm,
(g) feeding the waste water comprising the metal ions from the gold mining production system to the waste water processing unit,
wherein the first algae mat in the waste water processing unit filters the waste water to form (i) a third purified water stream and (ii) the first algae mat bound to the metal ions,
(h) removing the first algae mat bound to the metal ions from the waste water processing unit,
(i) extracting the metal ions bound to the first algae mat to produce the at least one metal, and
(j) extracting oil and/or ethanol from the first algae mat.